Oxadiazole compound, pharmaceutical composition containing same and application of oxadiazole compound
Patent Information
- Application Number
- CN202380033896.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-15
- Filing Date
- 2023-04-14
- Publication Date
- 2024-11-26
AI Technical Summary
Existing HDAC inhibitors are not selective for HDAC subtypes, resulting in significant side effects, and their pharmacokinetic properties and safety need to be improved.
Develop oxadiazole compounds as HDAC6-specific inhibitors with superior physicochemical properties and improved pharmacokinetic properties, reducing toxicity and side effects.
It achieves highly selective inhibition of HDAC6, reduces side effects, improves the solubility, stability and bioavailability of the compound, prolongs the duration of action, and reduces drug resistance.
Smart Images

Figure CN119032089A_ABST
Abstract
Description
Oxadiazole compound, pharmaceutical composition containing the same and use thereof Field of the Invention
[0001] The present application relates to oxadiazole compounds, pharmaceutical compositions containing the same, and uses thereof as HDAC6 inhibitors.
[0002] Background of the Invention
[0003] Histone deacetylases (HDACs) catalyze the deacetylation of histones or other proteins, playing important roles in a variety of biological processes, primarily through transcriptional repression. HDACs in the human body can be divided into four classes: Class I includes HDAC1, HDAC2, HDAC3, and HDAC8; Class II includes HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10; Class III includes SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7; and Class IV includes HDAC11. Class II HDACs are further divided into subtypes IIa (HDAC4, HDAC5, HDAC7, and HDAC9) and IIb (HDAC6 and HDAC10).
[0004] HDAC6 primarily catalyzes the deacetylation of non-histone substrates, such as α-tubulin and Hsp90. HDAC6 is involved in the pathological processes of various diseases, including cancer, neurological diseases, infections, cardiovascular diseases, and immune and inflammatory diseases.
[0005] In the field of tumor treatment, most HDAC inhibitors are broad-spectrum inhibitors and are not selective for HDAC subtypes. The side effects of broad-spectrum HDAC family inhibitors are closely related to their inhibition of class I subtypes (especially HDAC1 and HDAC2).
[0006] SUMMARY OF THE INVENTION
[0007] The present application provides oxadiazole compounds, which can be used as HDAC6 inhibitors to prevent or treat HDAC6-related diseases. The compounds of the present application are highly selective for HDAC6, thus avoiding the side effects of HDAC broad-spectrum inhibitors. In addition, the compounds of the present invention also have better physicochemical properties (such as solubility, physical and / or chemical stability), improved pharmacokinetic properties (such as improved bioavailability, improved metabolic stability, suitable half-life and duration of action), improved safety (lower toxicity (such as reduced cardiotoxicity) and / or less side effects), less prone to drug resistance and other more excellent properties.
[0008] One aspect of the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein the compound has the structure of Formula (I):
[0009] in
[0010] L is selected from a direct bond, -C 1-6 Alkylene-, -C 2-6 Alkenylene- and -C 2-6 Alkynylidene-;
[0011] X is CR 6 or N;
[0012] Y is CR 4 or N;
[0013] Z is CR 5 or N;
[0014] R 1 Selected from H, halogen, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R a 、-OC(=O)R a 、-OC(=O)NR a R b 、-C(=O)OR a 、-OR a 、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR a R b 、-NR a R b 、-C(=O)NR a R b 、-NR a -C(=O)R b 、-NR a -C(=O)OR b 、-NR a -S(=O)2-R b 、-NR a -C(=O)-NR a R b 、-C1-6 Alkylene-OR a 、-C 1-6 Alkylene-NR a R b and -OC 1-6 Alkylene-NR a R b ;
[0015] R 2 and R 3 Each independently selected from H, halogen, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R a 、-OC(=O)R a 、-OC(=O)NR a R b 、-C(=O)OR a 、-OR a 、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR a R b 、-NR a R b 、-C(=O)NR a R b 、-NR a -C(=O)R b 、-NR a -C(=O)OR b 、-NR a -S(=O)2-R b 、-NR a -C(=O)-NR a R b 、-C 1-6 Alkylene-OR a 、-C 1-6 Alkylene-NR a R b and -OC 1-6 Alkylene-NR a R b ; or R 2 and R 3 Together they form an oxo group (=O); or R 2 and R 3Together with the carbon atom to which it is connected, it forms C 3-6 Cycloalkyl or 3-10 membered heterocyclic group;
[0016] R 4 、R 5 and R 6 Each independently selected from H, halogen, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R a 、-OC(=O)R a 、-OC(=O)NR a R b 、-C(=O)OR a 、-OR a 、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR a R b 、-NR a R b 、-C(=O)NR a R b 、 -NR a -C(=O)R b 、-NR a -C(=O)OR b 、-NR a -S(=O)2-R b 、-NR a -C(=O)-NR a R b 、-C 1-6 Alkylene-OR a 、-C 1-6 Alkylene-NR a R b and -OC 1-6 Alkylene-NR a R b ;
[0017] R a and R b Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12Aralkyl;
[0018] The above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl groups are each optionally substituted at each occurrence with one or more substituents independently selected from the group consisting of halogen, -OH, =O, -NH2, -CN, -NO2, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R c 、-OC(=O)R c 、-OC(=O)NR c R d 、-C(=O)OR c 、-OR c 、-SR c 、-S(=O)R c 、-S(=O)2R c 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)NR c R d 、-NR c -C(=O)R d 、-NR c -C(=O)OR d 、-NR c -S(=O)2-R d 、-NR c -C(=O)-NR c R d 、-C 1-6 Alkylene-OR c 、-C 1-6 Alkylene-NR c R d and -OC 1-6 Alkylene-NR c R d The alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl groups are further optionally substituted by one or more substituents independently selected from the following: halogen, -OH, =O, -C(=O)O-tert-butyl, -NH2, -CN, -NO2, C 1-6 Alkyl, halogenated C 1-6 Alkyl, -OC 1-6 Alkyl, -O-halogenated C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10Aryl, 5-14 membered heteroaryl and C 6-12 aralkyl; and
[0019] R c and R d Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 Aralkyl, said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl further optionally substituted by one or more substituents independently selected from the following: halogen, -OH, =O, -C(=O)O-tert-butyl, -NH2, -CN, -NO2, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 Aralkyl.
[0020] Another aspect of the present invention provides a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound or prodrug thereof and one or more pharmaceutically acceptable carriers, wherein the pharmaceutical composition is preferably a solid preparation, a liquid preparation or a transdermal preparation.
[0021] Another aspect of the present invention provides use of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound or prodrug thereof, or a pharmaceutical composition of the present invention in the preparation of a medicament for preventing or treating an HDAC6-related disease.
[0022] Another aspect of the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound or prodrug thereof, or a pharmaceutical composition of the present invention, for use in preventing or treating HDAC6-related diseases.
[0023] Another aspect of the present invention provides a method for preventing or treating an HDAC6-related disease, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound or prodrug thereof, or a pharmaceutical composition of the present invention.
[0024] Detailed Description of the Invention
[0025] definition
[0026] Unless otherwise defined below, all technical and scientific terms used herein are intended to have the same meaning as those commonly understood by those skilled in the art. References to technology used herein are intended to refer to technology commonly understood in the art, including variations of technology or substitutions of equivalent technology that would be apparent to those skilled in the art. While it is believed that the following terms are well understood by those skilled in the art, the following definitions are set forth to better explain the present invention.
[0027] The terms "comprises," "comprising," "having," "containing," or "involving," and other variations thereof herein, are inclusive or open-ended and do not exclude additional unrecited elements or method steps.
[0028] As used herein, the term "alkylene" refers to a saturated divalent hydrocarbon group, preferably a saturated divalent hydrocarbon group having 1, 2, 3, 4, 5 or 6 carbon atoms, such as methylene, ethylene, propylene or butylene.
[0029] As used herein, the term "alkyl" is defined as a straight or branched chain saturated aliphatic hydrocarbon. In some embodiments, the alkyl group has 1 to 12, such as 1 to 6, carbon atoms. For example, as used herein, the term "C 1-6 "Alkyl" refers to a linear or branched group of 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl or n-hexyl), which is optionally substituted with one or more (e.g., 1 to 3) suitable substituents such as halogen (in which case the group is referred to as "haloalkyl") (e.g., CF3, C2F5, CHF2, CH2F, CH2CF3, CH2Cl or -CH2CH2CF3, etc.). The term "C 1-4 "Alkyl" refers to a linear or branched aliphatic hydrocarbon chain of 1 to 4 carbon atoms (ie, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).
[0030] As used herein, the term "alkenyl" means a linear or branched monovalent hydrocarbon radical containing one or more double bonds and having 2 to 6 carbon atoms ("C 2-6The alkenyl group is, for example, -CH=CH2, -CH2CH=CH2, -C(CH3)=CH2, -CH2-CH=CH-CH3, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl and 4-methyl-3-pentenyl. When the compound of the present invention contains an alkenyl group, the compound may be in the pure E (entgegen) form, the pure Z (zusammen) form or any mixture thereof. The term "alkenylene" is a corresponding divalent group, including, for example, "C 2-6 Alkenylene", "C 2-4 Specific examples include, but are not limited to, -CH=CH-, -CH2CH=CH-, -C(CH3)=CH-, butenylene, pentenylene, hexenylene, etc.
[0031] As used herein, the term "alkynyl" refers to a monovalent hydrocarbon radical containing one or more triple bonds, preferably having 2, 3, 4, 5 or 6 carbon atoms, such as ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl, etc. The alkynyl group is optionally substituted with one or more (such as 1 to 3) identical or different substituents. The term "alkynylene" is a corresponding divalent radical, including, for example, "C 2-8 Alkynylidene", "C 2-6 Alkynylidene", "C 2-4 Examples include, but are not limited to, The alkynylene group is optionally substituted with one or more (such as 1 to 3) substituents which may be the same or different.
[0032] As used herein, the terms "cycloalkylene", "cycloalkyl" and "hydrocarbon ring" refer to saturated (i.e., "cycloalkylene" and "cycloalkyl") or unsaturated (i.e., having one or more double bonds and / or triple bonds within the ring) monocyclic or polycyclic hydrocarbon rings having, for example, 3-10 (suitably 3-8, more suitably 3-6) ring carbon atoms, including but not limited to (cyclo)propyl, (cyclo)butyl, (cyclo)pentyl, (cyclo)hexyl, (cyclo)heptyl, (cyclo)octyl, (cyclo)nonyl, (cyclo)hexenyl, and the like.
[0033] As used herein, the term "cycloalkyl" refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (e.g., a monocyclic ring such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or a bicyclic ring, including spirocyclic, fused or bridged systems (such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl or bicyclo[5.2.0]nonyl, decalinyl, etc.), which is optionally substituted with one or more (such as one to three) suitable substituents. The cycloalkyl group has 3 to 15 carbon atoms. For example, the term "C 3-6 "Cycloalkyl" refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring of 3 to 6 ring carbon atoms (for example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), which is optionally substituted by 1 or more (such as 1 to 3) suitable substituents, for example methyl substituted cyclopropyl.
[0034] As used herein, the term "heterocyclyl" refers to a saturated or unsaturated monovalent monocyclic or bicyclic group having 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms and one or more (e.g., one, two, three or four) selected from O, S, S(=O), S(=O)2 and NR a A heteroatom-containing group, wherein R a Represents a hydrogen atom or C 1-6 Alkyl or halo-C 1-6 alkyl; the heterocyclyl may be attached to the rest of the molecule via any of the carbon atoms or the nitrogen atom (if present). In particular, a 3-10 membered heterocyclyl is a group having 3-10 carbon atoms and heteroatoms in the ring, such as, but not limited to, an oxirane, an aziridine, an azetidinyl, an oxetanyl, an tetrahydrofuranyl, a dioxolyl, a pyrrolidinyl, a pyrrolidonyl, an imidazolidinyl, a pyrazolidinyl, a pyrrolinyl, a tetrahydropyranyl, a piperidinyl, a morpholinyl, a dithianyl, a thiomorpholinyl, a piperazinyl or a trithianyl.
[0035] As used herein, the term "heterocyclyl" encompasses a cyclic structure, and the connection point of the cyclic structure to the other groups can be on any ring in the cyclic structure. Therefore, the heterocyclyl of the present invention also includes but is not limited to heterocyclyl and heterocyclyl, heterocyclyl and cycloalkyl, monoheterocyclyl and monoheterocyclyl, monoheterocyclyl and monocycloalkyl, such as 3-7 membered (mono) heterocyclyl and 3-7 membered (mono) heterocyclyl, 3-7 membered (mono) heterocyclyl and (mono) cycloalkyl, 3-7 membered (mono) heterocyclyl and C 4-6(Mono)cycloalkyl, examples of which are not limited to pyrrolidinyl and cyclopropyl, cyclopentyl and aziridine, pyrrolidinyl and cyclobutyl, pyrrolidinyl and pyrrolidinyl, pyrrolidinyl and piperidinyl, pyrrolidinyl and piperazinyl, piperidinyl and morpholinyl,
[0036] As used herein, the term "heterocyclyl" encompasses bridged heterocyclyls and spiro heterocyclyls.
[0037] As used herein, the term "bridged heterocycle" refers to a cyclic structure containing one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen atoms, nitrogen atoms, and / or sulfur atoms) formed by two saturated rings sharing two ring atoms that are not directly connected, including but not limited to 7-10 membered bridged heterocycles, 8-10 membered bridged heterocycles, 7-10 membered nitrogen-containing bridged heterocycles, 7-10 membered oxygen-containing bridged heterocycles, 7-10 membered sulfur-containing bridged heterocycles, etc., for example The "nitrogen-containing bridged heterocycle", "oxygen-containing bridged heterocycle" and "sulfur-containing bridged heterocycle" optionally further contain one or more other heteroatoms selected from oxygen, nitrogen and sulfur.
[0038] As used herein, the term "spiroheterocycle" refers to a cyclic structure containing one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen atoms, nitrogen atoms, sulfur atoms) formed by two or more saturated rings sharing a ring atom, including but not limited to 5-10 membered spiroheterocycles, 6-10 membered spiroheterocycles, 6-10 membered nitrogen-containing spiroheterocycles, 6-10 membered oxygen-containing spiroheterocycles, 6-10 membered sulfur-containing spiroheterocycles, etc., for example The "nitrogen-containing spiroheterocycle", "oxygen-containing spiroheterocycle" and "sulfur-containing spiroheterocycle" optionally further contain one or more other heteroatoms selected from oxygen, nitrogen and sulfur. The term "6-10 membered nitrogen-containing spiroheterocyclyl" refers to a spiroheterocyclyl containing 6-10 ring atoms, at least one of which is a nitrogen atom.
[0039] As used herein, the term "aryl" refers to an all-carbon monocyclic or fused-ring polycyclic aromatic group having a conjugated π electron system. For example, as used herein, the term "C 6-14 "Aryl" means an aromatic group containing 6 to 14 carbon atoms, such as phenyl or naphthyl. The aryl group is optionally substituted by one or more (such as 1 to 3) suitable substituents (e.g., halogen, -OH, -CN, -NO2, C 1-6 alkyl, etc.) substituted.
[0040] The term "aralkyl" preferably refers to an alkyl group substituted with an aryl group, wherein the aryl group and the alkyl group are as defined herein. Typically, the aryl group may have 6 to 14 carbon atoms, and the alkyl group may have 1 to 6 carbon atoms. Exemplary aralkyl groups include, but are not limited to, benzyl, phenylethyl, phenylpropyl, and phenylbutyl.
[0041] As used herein, the term "heteroaryl" or "heteroaromatic ring" refers to a monocyclic or polycyclic aromatic group containing one or more identical or different heteroatoms, including monocyclic heteroaryl groups and bicyclic or polycyclic ring systems containing at least one heteroaromatic ring (an aromatic ring system containing at least one heteroatom), which can have 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, for example 5, 6, 7, 8, 9 or 10 ring atoms. The heteroatom can be oxygen, nitrogen or sulfur. The carbon atoms and heteroatoms on the heteroaryl are optionally substituted with oxo groups (for example, to form C=O, S(=O) or S(=O)2).
[0042] As used herein, the term "5-10 membered heteroaryl" or "5-10 membered heteroaromatic ring" means a heteroaryl group (heteroaromatic ring) containing 5 to 10 (e.g., 5 to 6) ring atoms, including a 5-10 membered nitrogen-containing heteroaryl group, a 5-10 membered oxygen-containing heteroaryl group, a 5-10 membered sulfur-containing heteroaryl group, a 5-6 membered nitrogen-containing heteroaryl group, a 5-6 membered oxygen-containing heteroaryl group, a 5-6 membered sulfur-containing heteroaryl group, etc. The "nitrogen-containing heteroaryl group," "oxygen-containing heteroaryl group," and "sulfur-containing heteroaryl group" each optionally contain one or more other heteroatoms selected from oxygen, nitrogen, and sulfur. Examples include, but are not limited to, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, etc., or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., as well as 5-10 membered cyclic groups containing these groups.
[0043] As used herein, the term "heteroaryl" encompasses a cyclic structure, and the point of connection of the cyclic structure to the other groups can be on any ring in the cyclic structure. Therefore, the heteroaryl groups of the present invention also include, but are not limited to, (mono)heteroaryl and (mono)heteroaryl, (mono)heteroaryl and (mono)heterocyclyl, and (mono)heteroaryl and (mono)cycloalkyl, such as 5-6 membered (mono)heteroaryl and 5-6 membered (mono)heteroaryl, 5-6 membered (mono)heteroarylphenyl, 5-6 membered (mono)heteroaryl and 5-6 membered (mono)heterocyclyl, or 5-6 membered (mono)heteroaryl and C 4-6 (mono)cycloalkyl (e.g., 5-6 membered heteroarylcyclobutyl, 5-6 membered heteroarylcyclopentyl or 5-6 membered heteroarylcyclohexyl), examples of which are not limited to indolyl, isoindolyl, indazolyl, benzimidazole, quinolinyl, isoquinolinyl, wait.
[0044] As used herein, the term "halo" or "halogen" group is defined to include F, Cl, Br, or I.
[0045] The term "alkylthio" as used herein, means an alkyl group, as defined above, appended to the parent molecular moiety through a sulfur atom. 1-6 Representative examples of alkylthio include, but are not limited to, methylthio, ethylthio, tert-butylthio, and hexylthio.
[0046] As used herein, the term "nitrogen-containing heterocycle" refers to a saturated or unsaturated monocyclic or bicyclic group having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 carbon atoms and at least one nitrogen atom in the ring, which may optionally further contain one or more (e.g., one, two, three or four) ring members selected from N, O, C=O, S, S=O and S(=O); the nitrogen-containing heterocycle is linked to the rest of the molecule via the nitrogen atom. The nitrogen-containing heterocycle is preferably a saturated nitrogen-containing monocyclic ring. In particular, the 3- to 14-membered nitrogen-containing heterocycle is a group having 3-14 carbon atoms and heteroatoms (at least one of which is a nitrogen atom) in the ring, including but not limited to a three-membered nitrogen-containing heterocycle (such as aziridine), a four-membered nitrogen-containing heterocycle (such as azetidinyl), a five-membered nitrogen-containing heterocycle (such as pyrrolyl, pyrrolidinyl (pyrrolidine ring), pyrrolinyl, pyrrolidonyl, imidazolyl, imidazolidinyl, imidazolinyl, pyrazolyl, pyrazolinyl), a six-membered nitrogen-containing heterocycle (such as piperidinyl (piperidine ring), morpholinyl, thiomorpholinyl, piperazinyl), a seven-membered nitrogen-containing heterocycle, etc.
[0047] The term "substituted" means that one or more (e.g., one, two, three, or four) hydrogen atoms on the designated atom are replaced with a group selected from the indicated group, provided that the designated atom's normal valence is not exceeded in the current context and that the substitution results in a stable compound. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.
[0048] If a substituent is described as being "optionally substituted," the substituent may be (1) unsubstituted or (2) substituted. If a carbon of a substituent is described as being optionally substituted with one or more of the substituents listed, one or more hydrogens on the carbon (to the extent of any hydrogens present) may be replaced, individually and / or collectively, with independently selected optional substituents. If a nitrogen of a substituent is described as being optionally substituted with one or more of the substituents listed, one or more hydrogens on the nitrogen (to the extent of any hydrogens present) may each be replaced with an independently selected optional substituent.
[0049] If substituents are described as being "independently selected" from a group, each substituent is selected independently of the other. Thus, each substituent may be the same as or different from another (other) substituent.
[0050] As used herein, the term "one or more" means 1 or more than 1, such as 2, 3, 4, 5 or 10, where reasonable.
[0051] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent.
[0052] When a bond to a substituent is shown to pass through a bond connecting two atoms in a ring, then such substituent may be bonded to any ring atom in the substitutable ring.
[0053] The present invention also includes all pharmaceutically acceptable isotopically labeled compounds, which are identical to the compounds of the present invention except that one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature. Examples of isotopes suitable for inclusion in the compounds of the present invention include, but are not limited to, isotopes of hydrogen (e.g., deuterium (D, 2 H), tritium (T, 3 H)); carbon isotopes (e.g. 11 C. 13 C and 14 C); isotopes of chlorine (e.g. 36 Cl); isotopes of fluorine (e.g. 18 F); isotopes of iodine (such as 123 I and 125 I); isotopes of nitrogen (e.g. 13 N and 15 N); oxygen isotopes (e.g. 15 O. 17 O and 18 O); isotopes of phosphorus (such as 32 P); and sulfur isotopes (e.g. 35 S). Certain isotopically labeled compounds of the invention (e.g., those incorporating radioactive isotopes) are useful in drug and / or substrate tissue distribution studies (e.g., assays). 3 H) and carbon-14 (i.e. 14 C) are particularly useful for this purpose because they are easy to incorporate and easy to detect. 11 C. 18 F. 15 O and 13N) substitution can be used to examine substrate receptor occupancy in positron emission tomography (PET) studies. Isotopically labeled compounds of the present invention can be prepared by methods analogous to those described in the accompanying schemes and / or examples and preparations by using appropriate isotopically labeled reagents instead of the non-labeled reagents previously employed. Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent is isotopically substituted, for example, D2O, acetone-d6 or DMSO-d6.
[0054] It should also be understood that certain compounds of the present invention may be used therapeutically in free form or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof. In the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, metabolites, or prodrugs that, upon administration to a patient in need thereof, are capable of directly or indirectly providing a compound of the present invention or a metabolite or residue thereof. Therefore, when reference is made herein to a "compound of the present invention," such various derivative forms of the compound are also intended to be encompassed.
[0055] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof.
[0056] For a review of suitable salts see Stahl and Wermuth, “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of the compounds of the invention are known to those skilled in the art.
[0057] As used herein, the term "ester" refers to esters derived from the compounds of the general formulae herein, including physiologically hydrolyzable esters (which can be hydrolyzed under physiological conditions to release the compounds of the present invention in the form of free acid or alcohol). The compounds of the present invention themselves may also be esters.
[0058] The compounds of the present invention may exist in the form of solvates (preferably hydrates), wherein the compounds of the present invention contain a polar solvent as a structural element of the crystal lattice of the compound, in particular water, methanol or ethanol. The amount of polar solvent, in particular water, may be present in a stoichiometric or non-stoichiometric ratio.
[0059] Also included within the scope of the present invention are metabolites of the compounds of the present invention, i.e., substances formed in vivo upon administration of the compounds of the present invention. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic hydrolysis, and the like of the administered compound. Thus, the present invention includes metabolites of the compounds of the present invention, including compounds produced by contacting a compound of the present invention with a mammal for a period of time sufficient to produce a metabolic product thereof.
[0060] The present invention further includes within its scope prodrugs of the compounds of the present invention, which are certain derivatives of the compounds of the present invention that may themselves have little or no pharmacological activity and can be converted into compounds of the present invention having the desired activity by, for example, hydrolytic cleavage when administered to the body or thereon. Typically, such prodrugs will be functional group derivatives of the compounds that are readily converted into the desired therapeutically active compounds in vivo. Additional information on the use of prodrugs can be found in "Pro-drugs as Novel Delivery Systems," Volume 14, ACS Symposium Series (T. Higuchi and V. Stella) and "Bioreversible Carriers in Drug Design," Pergamon Press, 1987 (E.B. Roche, ed., American Pharmaceutical Association). Prodrugs of the present invention can be prepared, for example, by replacing appropriate functional groups present in the compounds of the present invention with certain moieties known to those skilled in the art as "pro-moieties" (e.g., as described in "Design of Prodrugs," H. Bundgaard (Elsevier, 1985)).
[0061] The present invention also encompasses compounds of the present invention that contain protecting groups. During any process for preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules involved, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved using conventional protecting groups, for example, those described in Protective Groups in Organic Chemistry, ed. JFW McOmie, Plenum Press, 1973; and TW Greene & P.GM Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Protecting groups can be removed at an appropriate subsequent stage using methods known in the art.
[0062] As used herein, the term "about" means within ±10%, preferably within ±5%, and more preferably within ±2% of the stated numerical value.
[0063] Compound
[0064] In some embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound, or prodrug thereof, wherein the compound has the structure of Formula (I):
[0065] in
[0066] L is selected from a direct bond, -C 1-6 Alkylene-, -C 2-6 Alkenylene- and -C 2-6 Alkynylidene-;
[0067] X is CR 6 or N;
[0068] Y is CR 4 or N;
[0069] Z is CR 5 or N;
[0070] R 1 Selected from H, halogen, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R a 、-OC(=O)R a 、-OC(=O)NR a R b 、-C(=O)OR a 、-OR a 、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR a R b 、-NR a R b 、-C(=O)NR a R b 、-NR a -C(=O)R b 、-NR a-C(=O)OR b 、-NR a -S(=O)2-R b 、-NR a -C(=O)-NR a R b 、-C 1-6 Alkylene-OR a 、-C 1-6 Alkylene-NR a R b and -OC 1-6 Alkylene-NR a R b ;
[0071] R 2 and R 3 Each independently selected from H, halogen, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R a 、-OC(=O)R a 、-OC(=O)NR a R b 、-C(=O)OR a 、-OR a 、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR a R b 、-NR a R b 、-C(=O)NR a R b 、-NR a -C(=O)R b 、-NR a -C(=O)OR b 、-NR a -S(=O)2-R b 、-NR a -C(=O)-NR a R b 、-C 1-6 Alkylene-OR a 、-C 1-6 Alkylene-NR a R b and -OC1-6 Alkylene-NR a R b ; or R 2 and R 3 Together they form an oxo group (=O); or R 2 and R 3 Together with the carbon atom to which it is connected, it forms C 3-6 Cycloalkyl or 3-10 membered heterocyclic group;
[0072] R 4 、R 5 and R 6 Each independently selected from H, halogen, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R a 、-OC(=O)R a 、-OC(=O)NR a R b 、-C(=O)OR a 、-OR a 、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR a R b 、-NR a R b 、-C(=O)NR a R b 、-NR a -C(=O)R b 、-NR a -C(=O)OR b 、-NR a -S(=O)2-R b 、-NR a -C(=O)-NR a R b 、-C 1-6 Alkylene-OR a 、-C 1-6 Alkylene-NR a R b and -OC 1-6 Alkylene-NR a R b ;
[0073] Ra and R b Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 Aralkyl;
[0074] The above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl groups are each optionally substituted at each occurrence with one or more substituents independently selected from the group consisting of halogen, -OH, =O, -NH2, -CN, -NO2, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R c 、 -OC(=O)R c 、-OC(=O)NR c R d 、-C(=O)OR c 、-OR c 、-SR c 、-S(=O)R c 、-S(=O)2R c 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)NR c R d 、-NR c -C(=O)R d 、-NR c -C(=O)OR d 、-NR c -S(=O)2-R d 、-NR c -C(=O)-NR c R d 、-C 1-6 Alkylene-OR c 、-C 1-6 Alkylene-NR c R d and -OC 1-6 Alkylene-NR c R dThe alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl groups are further optionally substituted by one or more substituents independently selected from the following: halogen, -OH, =O, -C(=O)O-tert-butyl, -NH2, -CN, -NO2, C 1-6 Alkyl, halogenated C 1-6 Alkyl, -OC 1-6 Alkyl, -O-halogenated C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 aralkyl; and
[0075] R c and R d Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 Aralkyl, said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl further optionally substituted by one or more substituents independently selected from the following: halogen, -OH, =O, -C(=O)O-tert-butyl, -NH2, -CN, -NO2, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 Aralkyl.
[0076] In a preferred embodiment, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein the compound has a structure of Formula (II) or Formula (III):
[0077] in:
[0078] L' is -C 1-6 Alkylene-, said alkylene being optionally substituted by one or more substituents independently selected from the group consisting of: -OH, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-14 membered heteroaryl; preferably, the alkylene group is optionally substituted by one or more substituents independently selected from the group consisting of -OH, cyclopropyl, and phenyl optionally substituted by one or more halogens;
[0079] The remaining groups are as defined herein.
[0080] In some embodiments, the present invention provides a compound of formula (I), formula (II) or formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein L is a direct bond or -C 1-6 Alkylene-, wherein the alkylene is optionally substituted by one or more substituents independently selected from the group consisting of: -OH, -OCH3, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-14 membered heteroaryl, said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl further optionally substituted by one or more halogen or C 1-6 Alkyl substitution.
[0081] In a preferred embodiment, L is a direct bond, methylene or ethylene, wherein the methylene and ethylene are optionally substituted with one or more substituents independently selected from the group consisting of -OH, -OCH3, methyl, cyclopropyl, phenyl, pyrazolyl, pyridyl, pyrimidinyl and pyridazinyl, which are optionally further substituted with one or more halogens and / or methyl;
[0082] In the most preferred embodiment, L is a direct bond, -CH2-, -CH2CH2-,
[0083] In some embodiments, the present invention provides a compound of Formula (I), Formula (II) or Formula (III), or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound, or prodrug thereof, wherein X, Y, and Z are each independently CH, CF, or N.
[0084] In some embodiments, the present invention provides a compound of Formula (I), Formula (II) or Formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein R 1 Selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-14 membered heteroaryl;
[0085] The alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -CN, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C6-10 Aryl, 5-14 membered heteroaryl, -C(=O)R c 、-OC(=O)R c 、-C(=O)OR c 、-OR c 、-S(=O)2R c 、-NR c R d 、-C(=O)NR c R d 、-NR c -C(=O)R d 、-NR c -C(=O)OR d 、-NR c -S(=O)2-R d and -NR c -C(=O)-NR c R d The above alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl groups are further optionally substituted by one or more substituents independently selected from the following: halogen (such as fluorine), -OH, =O, C 1-6 Alkyl (such as methyl), halogenated C 1-6 Alkyl (such as trifluoromethyl), -OC 1-6 Alkyl (e.g. methoxy) and -O-halogenated C 1-6 Alkyl (eg, trifluoromethoxy).
[0086] In some embodiments, the present invention provides a compound of Formula (I), Formula (II) or Formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein R c and R d Each occurrence is independently selected from H, C 1-6 Alkyl (such as methyl, ethyl, tert-butyl), C 3-10 Cycloalkyl (e.g. cyclopropyl), 3-10 membered heterocyclyl (e.g. pyrrolidinyl, morpholinyl or piperidinyl optionally substituted by F), C 6-10 Aryl (phenyl optionally substituted by F) and 5-14 membered heteroaryl (e.g. pyridyl), wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are further optionally substituted by one or more substituents independently selected from the group consisting of halogen (e.g. F), -OH, haloC 1-6 Alkyl (such as trifluoromethyl) and C 3-6 Cycloalkyl (eg, cyclopropyl).
[0087] In some embodiments, the present invention provides a compound of Formula (I), Formula (II) or Formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein R 1 is selected from methyl, cyclopropyl, cyclohexyl, tetrahydropyrrolyl, tetrahydropyranyl, piperidinyl, morpholinyl, phenyl, pyrazolyl, pyridinyl, pyrimidinyl, pyridazinyl and imidazopyridinyl; each of which is optionally substituted by one or more substituents independently selected from the following: -F, -Cl, -OH, -CN, -NH2, -CH3, -CF3, -CH2CF2CF3, -NHCH2CF3,
[0088] In some embodiments, the present invention provides a compound of Formula (I), Formula (II) or Formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein R 1 Has the following structure:
[0089] in:
[0090] U and V are each independently CR 8e R 8f NR 8g or O;
[0091] R 8a 、R 8b 、R 8c 、R 8d 、R 8e 、R 8f and R 8g are each independently H or halogen (e.g., F); and
[0092] R 9 For-OR c 、-NR c -C(=O)R d 、-NR c R d 、-NR c -C(=O)OR d 、-NR c -S(=O)2-R d 、-NR c -C(=O)-NR c R d 、-OC(=O)R c .
[0093] In some embodiments, the present invention provides a compound of Formula (I), Formula (II) or Formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein R 1 Selected from methyl,
[0094] In some embodiments, the present invention provides a compound of Formula (I), Formula (II) or Formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein R 2 and R 3 H or C 1-6 Alkyl, preferably H or methyl; or R 2 and R 3 Together they form an oxo group (=O); or R 2 and R 3 Together with the carbon atom to which it is connected, it forms C 3-6 Cycloalkyl, preferably cyclopropyl.
[0095] In some embodiments, the present invention provides a compound of Formula (I), Formula (II) or Formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein R 4 、R 5 and R 6 are each independently H or halogen; preferably, R 4 、R 5 and R 6 are each independently H or F.
[0096] The present invention encompasses compounds resulting from any combination of the various embodiments.
[0097] In a preferred embodiment, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein the compound is selected from:
[0098] Pharmaceutical compositions and methods of treatment
[0099] In some embodiments, the present invention provides a pharmaceutical composition comprising a prophylactically or therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof and one or more pharmaceutically acceptable carriers, wherein the pharmaceutical composition is preferably a solid preparation, a liquid preparation or a transdermal preparation.
[0100] In some embodiments, the present invention provides use of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound or prodrug thereof, or a pharmaceutical composition of the present invention in the preparation of a medicament for preventing or treating an HDAC6-related disease.
[0101] In some embodiments, the present invention provides a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound or prodrug thereof, or a pharmaceutical composition of the present invention, for use in preventing or treating HDAC6-related diseases.
[0102] In some embodiments, the present invention provides a method for preventing or treating an HDAC6-related disease, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, or a pharmaceutical composition of the present invention.
[0103] The HDAC6-associated diseases include, but are not limited to, cancer or proliferative diseases (e.g., lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, pancreatic cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphoma, myeloma, multiple myeloma, and solid tumors); Wilson's disease, spinocerebellar ataxia, prion disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, amyloidosis, Alzheimer's disease, Alexander's disease, alcoholic liver disease, cystic fibrosis, Pick's disease, spinal muscular atrophy, or Lewy body dementia. dementia; rheumatoid arthritis, osteoarthritis; rheumatoid spondylitis; psoriasis; inflammatory bowel disease; chronic inflammatory lung disease, eczema, asthma, ischemia / reperfusion injury, ulcerative colitis, acute respiratory distress syndrome, psoriatic arthritis, infectious arthritis, progressive chronic arthritis, osteoarthritis, osteoarthritis, traumatic arthritis, gouty arthritis, Reiter's syndrome, polychondritis, acute synovitis and spondylitis, glomerulonephritis, hemolytic anemia, aplastic anemia, idiopathic thrombocytopenic purpura, neutropenia, ulcerative colitis, Crohn's disease disease), host-versus-graft disease, graft-versus-host disease, allograft rejection, chronic thyroiditis, Graves' disease, scleroderma, diabetes mellitus, active hepatitis, primary biliary cirrhosis, myasthenia gravis, multiple sclerosis (MS), systemic lupus erythematosus, atopic dermatitis, contact dermatitis, sunburn, chronic renal insufficiency, Stevens-Johnson syndrome, idiopathic steatorrhea, sarcoidosis, Guillain-Barré syndrome, uveitis, conjunctivitis, keratoconjunctivitis, otitis media, periodontal disease, pulmonary fibrosis, asthma, bronchitis, rhinitis, sinusitis, pneumoconiosis, pulmonary insufficiency syndrome, emphysema, pulmonary fibrosis, or silicosis.
[0104] In the present invention, "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or vehicle that is administered together with the therapeutic agent and is suitable for contact with the tissues of humans and / or other animals without excessive toxicity, irritation, allergic response or other problems or complications corresponding to a reasonable benefit / risk ratio within the scope of reasonable medical judgment.
[0105] As used herein, unless otherwise indicated, the terms "treat," ...
[0106] As used herein, "subject" includes humans and non-human animals. Exemplary human subjects include human subjects suffering from diseases (e.g., the diseases described herein) (referred to as patients) or normal individuals. "Non-human animals" herein include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
[0107] In another embodiment, the pharmaceutical compositions of the present invention may further comprise one or more additional therapeutic or prophylactic agents.
[0108] Preparation method
[0109] In some embodiments, the compounds of the present application are synthesized by the following reaction scheme:
[0110] Route 1
[0111] wherein R is halogen, and the remaining groups are as defined herein.
[0112] Route 2
[0113] Wherein R is a halogen; PG is an amino protecting group; R 10 -C(=O)R d 、-C(=O)OR d 、-S(=O)2-R d 、C(=O)-NR c R d ; and the remaining groups are as defined herein.
[0114] Route 3
[0115] wherein R is halogen, and the remaining groups are as defined herein.
[0116] Route 4
[0117] Wherein R is a halogen; PG is an amino protecting group; R 10 -C(=O)R d 、-C(=O)OR d 、-S(=O)2-R d 、C(=O)-NR c R d ; and the remaining groups are as defined herein.
[0118] Route 5
[0119] wherein each group is as defined herein.
[0120] Route 6
[0121] Wherein PG is an amino protecting group; R 10 -C(=O)R d 、-C(=O)OR d 、-S(=O)2-R d 、C(=O)-NR c R d ; and the remaining groups are as defined herein. Example
[0122] The present invention is further described below with reference to examples, but these examples are not intended to limit the scope of the present invention.
[0123] The abbreviations used in this invention have the following meanings:
[0124] Example 1: (Compound 1)
[0125] Step 1: (Compound 1b)
[0126] Compound 1a (5 g, 36.72 mmol) was dissolved in chlorosulfonic acid (17.11 g, 146.88 mmol) and stirred at 120°C under nitrogen for 4 hours. LC-MS indicated the reaction was complete. The reaction solution was slowly poured into crushed ice, and the resulting solid was filtered and dried under vacuum to obtain 1b (7.3 g, 75%) as a white solid.
[0127] 1 H NMR (400MHz, DMSO-d6) δ8.35(d,J=1.9Hz,1H),7.80(dd,J=7.8,2.0Hz,1H),7.29(d,J=7.8Hz,1H),2.61(s,3H).
[0128] Step 2: (Compound 1c)
[0129] Compound 1b (6.3 g, 26.85 mmol) was dissolved in oxalyl chloride (30 g, 236.35 mmol) and stirred at 70°C under nitrogen for 2 hours. TLC indicated the reaction was complete, and the mixture was quenched with methanol. Excess oxalyl chloride was removed under reduced pressure, and the residue was dissolved in dichloromethane (20 mL). The mixture was cooled to 0°C, and methanol (10 mL) was slowly added dropwise. Stirring was continued at 0°C for 2 hours after the addition was complete. TLC indicated the reaction was complete. The reaction mixture was concentrated and purified by column chromatography to afford 1c (5.5 g, 82%) as a white solid.
[0130] 1 H NMR (400 MHz, chloroform-d) δ 8.76 (d, J = 1.8 Hz, 1H), 8.30 (dd, J = 7.9, 1.8 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 4.01 (s, 3H), 2.90 (s, 3H).
[0131] Step 3: (Compound 1d)
[0132] Compound 1c (2 g, 8.04 mmol), N-bromosuccinimide (1.57 g, 8.84 mmol), and azobisisobutyronitrile (132.02 mg, 0.80 mmol) were added to carbon tetrachloride (30 mL). The reaction mixture was stirred at 80°C under nitrogen for 8 hours. The reaction was monitored by TLC. The mixture was diluted with ethyl acetate (100 mL) and water (30 mL). The separated organic phase was washed with saturated brine (30 mL x 2), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to afford 1d (1.6 g, 35%) as a colorless oil.
[0133] 1 HNMR (400MHz, CDCl3) δ8.80–8.76(m,1H),8.41(dd,J=8.1,1.8Hz,1H),7.90(d,J=8.1Hz,1H),5.06(s,2H),4.03(s,3H).
[0134] Step 4: (Compound 1e)
[0135] Compounds 1d (1.6 g, 2.78 mmol), 1d' (0.6, 2.78 mmol), and sodium carbonate (0.69 g, 5.56 mmol) were added to a mixture of acetonitrile (30 mL) and water (6 mL). The reaction mixture was stirred at 25°C for 30 minutes, then heated to 80°C and stirred for 4 hours. The mixture was diluted with ethyl acetate (60 mL) and water (20 mL). The separated organic phase was washed with saturated brine (15 mL x 2), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to afford 1e (1.02 g, 86%) as a colorless oil.
[0136] ESI m / z[M+H] + =425.1.
[0137] 1 HNMR (400MHz, DMSO-d6) δ8.24(d,J=9.2Hz,2H),7.81(d,J=8.0Hz,1H),6.72(d,J=9.2Hz,1H),4.79(d,J=15.2Hz,1H),4.58(d, J=15.1Hz,1H),3.92(s,3H),3.55–3.41(m,2H),1.88–1.66(m,5H),1.51(d,J=12.1Hz,1H),1.27(d,J=9.6Hz,2H),1.10(s,9H).
[0138] Step 5: (Compound 1f)
[0139] Compound 1e (500 mg, 1.18 mmol) and hydrazine hydrate (2.06 g, 32.92 mmol, 80%) were added to methanol (6 mL). The reaction solution was stirred at 80°C in a sealed tube for 2 hours. LC-MS showed the reaction was complete. Excess methanol was removed under reduced pressure, filtered, and dried in vacuo to obtain 1f (495 mg, 99%) as a white solid.
[0140] ESI m / z[M+H] + =425.2.
[0141] Step 6: (Compound 20)
[0142] Compound 1f (495 mg, 1.17 mmol), triethylamine (0.53 g, 5.23 mmol), and difluoroacetic anhydride (0.45 g, 2.57 mmol) were added to dichloromethane (20 mL). The reaction was stirred at 25°C for 16 hours. LC-MS indicated the reaction was complete. The product was concentrated and purified by column chromatography to afford 20 (330 mg, 58%) as a white solid.
[0143] ESI m / z[M+H] + =485.1. 1H NMR(400MHz,DMSO-d6)δ8.40(d,J=1.5Hz,1H),8.36(dd,J=8.1,1.6Hz,1H),7.93( d,J=8.1Hz,1H),7.59(t,J=51.3Hz,1H),6.76(d,J=9.1Hz,1H),4.83(d,J=15.2Hz ,1H),4.62(d,J=15.2Hz,1H),3.54–3.41(m,2H),1.84(d,J=11.8Hz,2H),1.73(d, J=17.5Hz,3H),1.52(q,J=12.3,11.5Hz,1H),1.31(d,J=12.2Hz,2H),1.12(s,9H).
[0144] Step 7: (Compound 108)
[0145] Compound 20 (150 mg, 0.31 mmol) was dissolved in 4 M hydrogen chloride in ethyl acetate (20 mL). The reaction mixture was stirred at 25°C for 2 hours. LC-MS showed the reaction was complete. The mixture was concentrated to give 108 (130 mg, 100%) as a white solid.
[0146] ESI m / z[M+H] + =385.1. 1 H NMR(400MHz,DMSO-d6)δ8.40(d,J=1.5Hz,1H),8.36(dd,J=8.1,1.6Hz,1H),7.93( d,J=8.1Hz,1H),7.59(t,J=51.3Hz,1H),6.76(d,J=9.1Hz,1H),4.83(d,J=15.2Hz ,1H),4.62(d,J=15.2Hz,1H),3.47(dtd,J=21.6,10.8,5.2Hz,2H),1.84(d,J=11. 5Hz, 2H), 1.73 (d, J = 17.5Hz, 3H), 1.52 (d, J = 12.2Hz, 1H), 1.31 (d, J = 12.6Hz, 2H).
[0147] Step 8: (Compound 1)
[0148] To N,N-dimethylformamide (3 mL) were added compound 108 (65 mg, 0.15 mmol), difluoropropionic acid (20 mg, 0.18 mmol), N,N-diisopropylethylamine (39 mg, 0.3 mmol), and HATU (74 mg, 0.20 mmol), respectively. The reaction mixture was stirred at 25°C for 2 hours. LC-MS indicated completion of the reaction. The mixture was diluted with ethyl acetate (40 mL) and water (15 mL). The organic phase was separated, washed with saturated brine (15 mL x 2), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to afford 1 (26 mg, 36%) as a white solid.
[0149] ESI m / z[M+H] + =477.1. 1 H NMR (400MHz, DMSO-d6) δ7.97(d,J=9.3Hz,1H),7.77(d,J=1.5Hz,1H),7.74(dd,J=8.1,1.6Hz,1H),7.28(d,J=8.1Hz,1H),6.95(t,J=51.3Hz, 1H),4.14–3.91(m,2H),3.36–3.21(m,1H),3.01(td,J=11.0,4.2Hz,1H),1.28–1.03(m,6H),0.87(t,J=19.4Hz,3H),0.71(d,J=11.2Hz,2H).
[0150] Example 2: (Compound 2)
[0151] To a solution of compound 108 (71 mg, 0.17 mmol) and N,N-diisopropylethylamine (0.11 g, 0.85 mmol) in N,N-dimethylformamide (3 mL) was added difluoroacetic anhydride (59 mg, 0.34 mmol) dropwise at 25°C. After the addition was complete, the mixture was stirred for 1 hour. TLC indicated the reaction was complete. The mixture was diluted with ethyl acetate (40 mL) and water (15 mL). The separated organic phase was washed with saturated brine (15 mL x 2), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to afford 2 (36.2 mg, 46%) as a white solid.
[0152] ESI m / z[M+H] + =463.0. 1H NMR (400MHz, DMSO-d6) δ8.76(d,J=9.3Hz,1H),8.44–8.31(m,2H),7.92(d,J=8.1Hz,1H),7.60(t,J=51.3Hz,1H),6.03(t,J= 53.8Hz,1H),4.76–4.62(m,2H),3.99–3.87(m,1H),3.61(td,J=10.8,4.5Hz,1H),1.94–1.57(m,6H),1.32(d,J=25.9Hz,2H).
[0153] Example 3: (Compound 3)
[0154] Compound 108 (200 mg, 0.48 mmol) was dissolved in dichloromethane (4 mL), and N,N-diisopropylethylamine (156.27 mg, 0.50 mmol) and pentafluoropropionic anhydride (189.21 mg, 1.46 mmol) were added. The reaction mixture was stirred at 10°C for 14 hours. LCMS indicated the reaction was complete. The reaction mixture was poured into water and extracted with dichloromethane. The organic phase was washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to afford 3 (23 mg, 9%) as a white solid.
[0155] ESI m / z[MH] - =529.1. 1 H NMR (400MHz, DMSO-d6) δ9.44(d,J=9.1Hz,1H),8.39(d,J=1.5Hz,1H),8.35(dd,J=8.1,1.6Hz,1H),7.89(d,J=8.1Hz,1H),7.56(t,J=51.3Hz,1H),4.69( d,J=15.4Hz,1H),4.56(d,J=15.4Hz,1H),4.09–3.90(m,1H),3.63(td,J=11 .0,4.2Hz,1H),1.78(ddd,J=33.3,16.2,6.8Hz,6H),1.34(d,J=9.4Hz,2H).
[0156] Example 4: (Compound 4)
[0157] Compound 108 (200 mg, 0.48 mmol) was dissolved in dichloromethane (4 mL), and N,N-diisopropylethylamine (186.11 mg, 1.44 mmol) and cyclopropylsulfonyl chloride (80.98 mg, 0.58 mmol) were added. The reaction was stirred at 10°C for 14 hours. LCMS indicated the reaction was complete. The reaction solution was poured into water and extracted with dichloromethane. The organic phase was washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified on a preparative plate to afford 4 (27 mg, 12%) as a white solid.
[0158] ESI m / z[MH] - =487.2. 1 H NMR(400MHz,DMSO-d6)δ8.41(d,J=1.5Hz,1H),8.36(dd,J=8.1,1.6Hz,1H),7.89 (d,J=8.1Hz,1H),7.57(t,J=51.3Hz,1H),7.11(d,J=8.7Hz,1H),4.71(d,J=2.5H z,2H),3.52–3.37(m,2H),2.18(d,J=12.9Hz,1H),1.92(d,J=12.6Hz,1H),1.72( q,J=13.2,12.2Hz,3H),1.58–1.44(m,1H),1.37–1.22(m,3H),0.92–0.75(m,4H).
[0159] Example 5: (Compound 6)
[0160] First step (compound 6b)
[0161] Compound 6a (1 g, 3.41 mmol) was dissolved in acetonitrile (20 mL), and diisopropylethylamine (1.1 g, 8.53 mmol) and compound 1d' (730 mg, 3.41 mmol) were added. The mixture was stirred at room temperature for 30 minutes and then at 80°C overnight. The reaction mixture was washed with water, extracted with ethyl acetate, concentrated, and separated by column chromatography to yield compound 6b (1.2 g, 82%).
[0162] Step 2 to Step 5 (Compound 6)
[0163] Referring to the fifth to eighth steps of the synthetic route of Example 1, compound 6b was used instead of 1e in the fifth step, and difluoroacetic acid was used instead of difluoropropionic acid in the eighth step to obtain white solid 6.
[0164] ESI m / z[M+H] + =477.0. 1H NMR (400MHz, CDCl3) δ8.54(s,1H),8.50(d,J=8.0Hz,1H),8.17(d,J=8.0Hz,1H), 6.89(t,J=51.6Hz,1H),6.29(d,J=8.4Hz,1H),5.61(t,J=54.4Hz,1H), 4.62-4.60 (m,1H),3.77-3.74(m,1H),2.50-2.41(m,1H),2.22-2.16(m,1H),2.04-2.01(m, 1H),1.93-1.87(m,1H),1.81-1.78(m,1H),1.47-1.40(m,1H),1.37-1.28(m,2H).
[0165] Example 6: (Compound 7)
[0166] 1. (Compound 7b)
[0167] A solution of compound 7a (5.0 g, 23.6 mmol) and 4,4-dimethylcyclohexanone (5.9 g, 47.2 mmol) in methanol (100 mL) was stirred at room temperature for 1 hour. The mixture was cooled to 0°C, and sodium borohydride (3.6 g, 94.3 mmol) was added and stirred at room temperature for 2 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic phase was dried, concentrated, and stirred in hydrogen chloride (4 M solution in dioxane, 20 mL) for 1 hour. The mixture was filtered, and the filter cake was dissolved in water, neutralized with sodium bicarbonate, and extracted with ethyl acetate. The organic phase was dried and concentrated to afford 7b (5 g, 66%) as a light yellow oil.
[0168] 1 H NMR (400MHz, CDCl3) δ7.21-7.12(m,10H),4.01(d,J=7.2Hz,1H),3.84(d,J=7.6Hz,1H),2.23-2.16(m,1H),2. 04(s,3H),1.74-1.64(m,1H),1.531.45(m,1H),1.28-1.21(m,3H),1.17-0.96(m,3H),0.82(d,J=14.4Hz,6H).
[0169] 2. (Compound 7c)
[0170] Compound 7b (3.6 g, 11.1 mmol), N-Boc-O-toluenesulfonylhydroxylamine (16.0 g, 55.7 mmol), sodium bicarbonate (23.4 g, 278.7 mmol), and benzoic acid (6.8 g, 55.7 mmol) were added to chloroform (200 mL). Stirring was continued at room temperature for 1 hour. Cyclohexenone (16.0 g, 167.2 mmol) was then added and stirred overnight at room temperature. The reaction was quenched with water and extracted with dichloromethane. The organic phase was dried, concentrated, and separated by column chromatography to afford 7c (8.5 g, 64%) as a yellow oil.
[0171] 1 H NMR (400MHz, CDCl3) δ3.10-3.05(m,1H),2.89(d,J=5.6Hz,1H),2.54-2.46(m,1H),2.2 7-2.19(m,1H),2.10-1.91(m,2H),1.83-1.74(m,1H),1.68-1.60(m,1H),1.45(s,9H).
[0172] 3. (Compound 7d)
[0173] To a solution of compound 7c (2.5 g, 11.8 mmol) in dichloromethane (30 mL) at 0°C was added DAST (12.3 g, 59.2 mmol). The mixture was stirred at room temperature for 16 hours. The reaction mixture was poured into ice water and extracted with dichloromethane. The organic phase was dried, concentrated, and separated by column chromatography to afford 7d (5.0 g, 63%) as a yellow oil.
[0174] 1 H NMR (400MHz, CDCl3) δ2.88-2.81(m,2H),1.99-1.64(m,4H),1.62-1.55(m,2H),1.45(s,9H).
[0175] 4. (Compound 7e)
[0176] A solution of compound 7e (5.0 g, 21.5 mmol) in methanol / ammonia (100 mL) was stirred at room temperature for 3 days. The reaction solution was directly concentrated and separated by column chromatography to obtain 7e (1.8 g, 33%) as a white solid.
[0177] ESI m / z[M+H] + =251.1. 1H NMR(400MHz,DMSO-d6)δ6.89(d,J=9.6Hz,1H),3.50-3.35(m,1H),2.62-2.53(m,1H) ,2.06-1.93(m,1H),1.85-1.59(m,3H),1.48(s,2H),1.39(s,9H),1.36-1.15(m,2H).
[0178] 5. (Compound 7)
[0179] Referring to the synthetic route of compound 1 in Example 1, compound 7e was used instead of 1d' to obtain white solid 7.
[0180] ESI m / z[M+H] + =512.9. 1 H NMR (400MHz, CDCl3) δ8.50 (s, 1H), 8.38 (d, J = 7.6Hz, 1H), 7.43 (d, J = 8.4Hz, 1H), 7.06-6.78 (m, 2H), 4.69 (d, J = 14.4Hz, 1H), 4.50 (d, J = 14.0Hz, 1H),4.44-4.33(m,1H),3.96-3.90(m,1H),2.38-2.34(m,1H),2.24-2.1 9(m,1H),1.97-1.92(m,1H),1.88-1.67(m,3H),1.56(t,J=18.8Hz,3H).
[0181] Example 7: (Compound 10)
[0182] 1. (Compound 10a)
[0183] To a solution of 7e (0.2 g, 0.8 mmol) in DMF (1 mL) were added HATU (0.3 g, 0.8 mmol) and N,N-diisopropylethylamine (0.31 g, 2.4 mmol). The mixture was stirred at 25°C for 30 minutes, followed by the addition of difluoropropionic acid (0.11 g, 0.96 mmol), and the mixture was stirred at 20°C for 16 hours. Water was added to precipitate a solid, which was filtered to afford 10a (0.2 g, 73%) as a white solid.
[0184] ESI m / z[M+H] + =343.1.
[0185] 2. (Compound 10b)
[0186] To a solution of compound 10a (150 mg, 0.44 mmol) in dioxane (5 mL) was added a solution of hydrogen chloride in dioxane (1 mL, 4 M). The mixture was stirred at room temperature for 3 hours. The reaction mixture was directly concentrated to afford 10b (0.1 g, 94%) as a yellow oil.
[0187] ESI m / z[M+H] + =243.1.
[0188] 5. (Compound 10)
[0189] Referring to the synthetic route of compound 20 in Example 1, compound 10b was used instead of 1d′ in the fourth step to obtain white solid 10.
[0190] ESI m / z[MH] - =511.1. 1 H NMR (400MHz, DMSO-d6) δ8.70(d,J=9.2Hz,1H),8.48(d,J=1.5Hz,1H),8.40(dd,J=8.1,1.6Hz,1H),7.95(d,J=8.1Hz,1H),7.60(t,J=51.3Hz,1 H),4.88-4.73(m,2H),4.30-4.19(m,1H),4.18-4.04(m,1H),2.25(s,1H),2.02-1.83(m,3H),1.54(d,J=13.9Hz,2H),1.38(d,J=19.2Hz,3H).
[0191] Example 8: (Compound 21)
[0192] Referring to the synthetic route of compound 20 in Example 1, (1R,2R)-2-aminocyclohexane-1-ol was used instead of 1d′ in the fourth step to obtain 21 as a white solid.
[0193] ESI m / z[MH] - =384.1. 1 H NMR (400MHz, DMSO-d6) δ8.40-8.33(m,2H),7.88(d,J=8.1Hz,1H),7.56(t,J=51.3Hz,1H),4.84(d,J=5.0Hz,1H), 4.72-4.59(m,2H),3.59-3.49(m,2H),1.94(dd,J=27.5,11.9Hz,2H),1.65(d,J=15.7Hz,2H),1.37-1.14(m,4H).
[0194] Example 9: (Compound 24)
[0195] Referring to the synthesis method of compound 4 in Example 4, methylsulfonyl chloride was used instead of cyclopropylsulfonyl chloride to obtain white solid 24.
[0196] ESI m / z[M+H] + =463.2. 1 H NMR (400MHz, DMSO-d6) δ8.44(d,J=1.5Hz,1H),8.39(dd,J=8.1,1.6Hz,1H),7.92(d,J=8.2Hz,1H),7.60(t,J=51.3Hz,1H),7.13(d,J=8.3Hz,1H) ,4.72(s,2H),3.52-3.39(m,2H),2.84(s,3H),2.17-2.06(m,1H),1.99- 1.63(m,4H),1.47(dd,J=18.2,7.6Hz,1H),1.31(q,J=16.0,13.4Hz,2H).
[0197] Example 10: (Compound 39)
[0198] Referring to the synthesis method of compound 1 in Example 1, methyl 3-fluoro-4-methylbenzoate was used instead of p-toluic acid in the first step to obtain white solid 39.
[0199] ESI m / z[M+H] + =494.9. 1 H NMR(400MHz, DMSO-d6)δ8.58(d,J=9.6Hz,1H),8.30(d,J=0.8Hz,1H),8.25-8.22(m,1H),7.56(d,J=51.2Hz,1H),4 .77-4.66(m,2H),3.96-3.93(m,1H),3.65-3.61(m,1H),1.86-1.70(m,6H),1.54-1.44(m,3H),1.34-1.23(m,2H).
[0200] Example 11: (Compound 40)
[0201] Referring to the synthesis method of compound 1 in Example 1, methyl 3-fluoro-4-methylbenzoate was used instead of p-toluic acid in the first step, and difluoroacetic acid was used instead of difluoropropionic acid in the eighth step to obtain white solid 40.
[0202] ESI m / z[M+H2O] + =498.0.1 H NMR (400MHz, DMSO-d6) δ8.73(d,J=9.2Hz,1H),8.29(d,J=0.8Hz,1H),8.23(d,J=9.2Hz,1H),7.57(d,J=51.2Hz,1H),6 .00(d,J=53.6Hz,1H),4.78-4.67(m,2H),3.98-3.93(m,1H),3.61-3.55(m,1H),1.87-1.63(m,6H),1.35-1.23(m,2H).
[0203] Example 12: (Compound 47)
[0204] Referring to the synthesis method of compound 20 in Example 1, (3R,4R)-4-amino-3-hydroxytetrahydropyran was used instead of 1d' in the fourth step to obtain 47 as a white solid.
[0205] ESI m / z[M+H] + =387.9. 1 H NMR (400MHz, DMSO-d6) δ8.40(s,1H),8.38-8.36(m,1H),7.89(d,J=8.4Hz,1H),7.70-7.44(m,1H),5.23(d,J=5.2Hz,1H),4.77(d,J= 15.6Hz,1H),4.65(d,J=15.6Hz,1H),3.91-3.82(m,2H),3.69-3.57(m,2H),3.42-3.34(m,1H),3.15-3.09(m,1H),1.94-1.90(m,2H).
[0206] Example 13: (Compound 49)
[0207] Referring to the synthesis method of compound 20 in Example 1, (3R,4R)-3-amino-4-hydroxytetrahydropyran was used instead of 1d' in the fourth step to obtain 49 as a white solid.
[0208] ESI m / z[M+H] + =387.9. 1H NMR (400MHz, DMSO-d6) δ8.40 (s, 1H), 8.38-8.36 (m, 1H), 7.89 (d, J = 8.4Hz, 1H), 7.7 0-7.44(m,1H),5.23(d,J=5.2Hz,1H),4.77(d,J=15.6Hz,1H),4.65(d,J=15.6Hz,1 H),3.91-3.82(m,2H),3.69-3.57(m,2H),3.42-3.34(m,1H),3.15-3.09(m,1H),1.94-1.90(m,2H).
[0209] Example 14: (Compound 55)
[0210] Referring to the synthesis method of compound 2 in Example 2, trifluoroacetic anhydride was used instead of difluoroacetic anhydride to obtain white solid 55.
[0211] ESI m / z[MH] - =479.2. 1 H NMR (400MHz, DMSO-d6) δ9.36(d,J=9.1Hz,1H),8.46-8.33(m,2H),7.93(d,J=8.1Hz,1H),7.60(t,J=51.3Hz,1H),4.73(d,J=15.5Hz,1H) ,4.63(d,J=15.4Hz,1H),4.03-3.90(m,1H),3.69-3.59(m,1H),1.82(d,J=17.0Hz,4H),1.73(d,J=11.0Hz,2H),1.36(d,J=10.4Hz,2H).
[0212] Example 15: (Compound 60)
[0213] Refer to the synthesis method of compound 20 in Example 1. Substituting 1d' with 3-chlorobenzylamine, a white solid 60 was obtained.
[0214] ESI m / z[MH] - =410.0. 1 H NMR (400MHz, DMSO-d6) δ8.51(d,J=1.5Hz,1H),8.41(dd,J=8.1,1.6Hz,1H),7.90-7.86(m,1H),7.75-7.45(m,5H),4.54(s,2H),4.53(s,2H).
[0215] Example 16: (Compound 61)
[0216] Refer to the synthesis method of compound 1 in Example 1. In the fourth step, 7e is used instead of 1d', and in the eighth step, difluoroacetic acid is used instead of difluoropropionic acid to obtain white solid 61.
[0217] ESI m / z[M+H] + =499.1. 1 H NMR (400MHz, DMSO-d6) δ9.28(d,J=9.7Hz,1H),8.44(d,J=1.5Hz,1H),8.39(dd,J= 8.1,1.6Hz,1H),7.94(d,J=8.2Hz,1H),7.60(t,J=51.3Hz,1H),6.19(t,J=53.7Hz, 1H),4.78(d,J=15.6Hz,1H),4.74-4.62(m,1H),4.57(d,J=15.5Hz,1H),3.77(td, J=11.7,3.9Hz,1H),2.26-1.99(m,3H),1.87(d,J=13.1Hz,2H),1.64-1.48(m,1H).
[0218] Example 17: (Compound 62)
[0219] To a solution of compound 108 (100 mg, 0.65 mol) in acetonitrile (2 mL) was added N,N-diisopropylethylamine (100 mg, 0.78 mmol) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (91 mg, 0.39 mmol) with stirring at 25°C. The mixture was then reacted at 80°C for 16 hours. The reaction mixture was purified by reverse-phase column chromatography to afford compound 62 (50 mg, 41%) as a white solid.
[0220] ESI m / z[M+H] + =467.2. 1H NMR (400MHz, DMSO-d6) δ8.45(d,J=1.5Hz,1H),8.40(dd,J=8.1,1.6Hz,1H),7.91(d,J =8.1Hz,1H),7.60(t,J=51.3Hz,1H),4.75-4.61(m,2H),3.48(t,J=9.0Hz,1H),3.28( s,1H),2.79-2.66(m,1H),2.48-2.34(m,1H),2.14-2.02(m,1H),1.91(d,J=11.6Hz,1 H), 1.72 (s, 3H), 1.38 (d, J = 12.2Hz, 1H), 1.23 (d, J = 9.4Hz, 1H), 1.03 (d, J = 6.4Hz, 1H).
[0221] Example 18: (Compounds 70i-A, 70i-B, 70i-BA, 70i-BB)
[0222] 1. (Compound 70c)
[0223] To a solution of compound 70a (2.34 g, 25.25 mmol) in tetrahydrofuran (40 mL) was added n-butyllithium (16.8 mL, 1.5 M in THF) at -78°C and stirred at this temperature for 1 hour. Then, a solution of compound 70b (3.46 g, 25.25 mmol) in tetrahydrofuran (20 mL) was slowly added dropwise. Stir at this temperature for 3 hours, then warm to room temperature and stir overnight. The reaction was quenched with dilute hydrochloric acid, extracted with dichloromethane, concentrated, and separated by column chromatography to afford compound 70c (2.0 g, 40%) as a white solid.
[0224] 2. (Compound 70d)
[0225] Compound 70c (1.94 g, 9.78 mmol) was added to hydrochloric acid (6 M, 20 mL) at 0°C, followed by the slow addition of a 5 mL aqueous solution of sodium nitrite (1.69 g, 24.5 mmol). The mixture was stirred at room temperature for 2 hours. The mixture was extracted with dichloromethane, concentrated, and separated by column chromatography to afford 70d (1.51 g, 68%) as a yellow solid.
[0226] 3. (Compound 70e)
[0227] To a solution of compound 70d (1.51 g, 6.68 mmol) in methanol (40 mL) was added sodium borohydride (304 mg, 8 mmol) at 0°C. The mixture was stirred for 2 hours, washed with water, extracted with dichloromethane, and concentrated to afford 70e (1.5 g, 98%) as a yellow solid.
[0228] 4. (Compounds 70f-P1, 70f-P2)
[0229] A solution of compound 70e (1.5 g, 6.5 mmol) and Pd / C (750 mg, 10%) in methanol (200 mL) was stirred at 70°C under a hydrogen atmosphere (4.0 MPa) for 2 days. The mixture was filtered and the filtrate was separated by column chromatography to obtain yellow oils 70f-P1 (400 mg, 27%) and 70f-P2 (400 mg, 27%).
[0230] 70f-P1: 1 H NMR (400MHz, DMSO-d6): δ8.51-8.47(m,2H),7.79-7.68(m,2H),7.46(d,J=10.4Hz,1H),4.79(d,J=10 .4Hz,1H),7.26-7.20(m,2H),5.47(s,1H),4.91(d,J=4.8Hz,1H),4.25(d,J=5.2Hz,1H),1.94(s,2H).
[0231] 70f-P2: 1 H NMR (400MHz, DMSO-d6): δ8.48-8.41(m,2H),7.68-7.59(m,2H),7.23-7.15(m ,4H),5.46(s,1H),4.79(d,J=6.0Hz,1H),4.19(d,J=6.4Hz,1H),2.04(s,2H).
[0232] 5. (Compound 70i-A)
[0233] Refer to the synthetic route of compound 20 in Example 1. Substituting compound 70f-P1 for 1d', a white solid 70i-A was obtained as a racemate.
[0234] ESI m / z[M+H] + =485.9. 1 H NMR (400MHz, DMSO-d6) δ8.51-8.47(m,2H),8.35-8.33(m,2H),7.93(d,J=8.4Hz,1H),7.70-7.43(m,4H) ,7.24-7.18(m,3H),5.96(d,J=5.6Hz,1H),5.61-5.58(m,1H),5.44(d,J=6.0Hz,1H),5.14-5.01(m,2H).
[0235] 6. (Compound 70i-B)
[0236] Refer to the synthetic route of compound 20 in Example 1. Substituting compound 70f-P2 for 1d', a white solid 70i-B was obtained as a racemate.
[0237] ESI m / z[M+H] + =485.9. 1 H NMR (400MHz, DMSO-d6) δ8.58(d,J=4.0Hz,1H),8.38(d,J=4.4Hz,1H),8.30-8.28(m,1H),8.24(s,1H),7.89(d,J=8.4Hz,1H),7.80-7.74(m,2H) ,7.66-7.40(m,3H),7.37-7.31(m,1H),7.22-7.19(m,1H),6.99(d,J=6 .0Hz,1H),5.47-5.44(m,1H),5.18(d,J=8.4Hz,1H),5.14-5.02(m,2H).
[0238] 7. (Compounds 70i-BA, 70i-BB)
[0239] Compound 70i-B (240 mg, 0.49 mmol) was subjected to chiral separation (column: IC, mobile phase: Hex / EtOH / TFA 50 / 50 / 0.3, flow rate: 25 mL / min, detection wavelength: 254 nM) to give white solid compounds 70i-BA (retention time: 21.264 minutes, 50 mg, 21%) and compound 70i-BB (retention time: 29.823 minutes, 50 mg, 21%), both of which were chirally pure compounds.
[0240] 70i-BA:ESI m / z[M+H] + =486.0. 1 H NMR (400MHz, DMSO-d6) δ8.59(s,1H),8.40(s,1H),8.29(d,J=8.0Hz,1H),8.25(s,1H),7.89(d,J=8.4Hz,1H),7.80-7.74(m, 2H),7.66-7.63(m,1H),7.53-7.41(m,2H),7.33(m,1H),7.23(m,1H),6.03(s,1H),5.47(d,J=7.2Hz,1H),5.19-5.00(m,3H).
[0241] 70i-BB:ESI m / z[M+H] + =485.9. 1H NMR (400MHz, DMSO-d6) δ8.58(d,J=4.0Hz,1H),8.38(d,J=4.4Hz,1H),8.30-8.28(m,1H),8.25(s,1H),7.89(d,J=8.0Hz,1H),7.8 0-7.75(m,2H),7.66-7.41(m,3H),7.34-7.31(m,1H),7.23-7.20(m,1H),6.01(s,1H),5.46(d,J=8.0Hz,1H),5.20-5.02(m,3H).
[0242] Example 19: (Compound 72)
[0243] 1. (Compound 72b)
[0244] Compound 72a (1 g, 6.21 mmol), 4-bromo-1-methyl-1H-pyrazole (1.98 g, 6.21 mmol), potassium carbonate (2.57 g, 18.6 mmol), and 1,1'-bis(diphenylphosphinoferrocenedichloropalladium) (0.55 g, 0.75 mmol) were added to a mixture of dioxane (5 mL) and water (1 mL) and stirred at 80°C for 16 hours. The reaction solution was poured into water, extracted with dichloromethane, concentrated, and purified by column chromatography to afford 72b (900 mg, 53%) as a white solid.
[0245] ESI m / z[M+H] + =274.1.
[0246] 2. (Compound 72c)
[0247] Compound 72b (500 mg, 2.12 mmol) was added to a dichloromethane (5 mL) solution, and trifluoroacetic acid (2 mL) was added with stirring for 2 hours. The reaction solution was concentrated to obtain a yellow oil 72c (300 mg, 95%).
[0248] 3. (Compound 72)
[0249] Refer to the synthetic route of compound 20 in Example 1. Substituting compound 72c for 1d', a white solid 72 was synthesized through three steps.
[0250] ESI m / z[M+H] + =444.2. 1H NMR (400MHz, DMSO-d6) δ8.61-8.57(m,1H),8.46(dd,J=8.1,1.6Hz,1H),8.06(s,1H),7.91(d,J=8.2Hz,1H),7.7 9(s,1H),7.77-7.61(m,3H),7.54(td,J=7.6,1.4Hz,1H),7.43(td,J=7.6,1.6Hz,1H),4.83(s,2H),3.81(s,3H).
[0251] Example 20: (Compounds 79i, 79i-A, 79i-B)
[0252] 1. (Compound 79c)
[0253] A mixture of compound 79a (2 g, 16.6 mmol), sodium tert-butoxide (3.8 g, 39.6 mmol), and XPhosPd-G3 (1.41 g, 1.66 mmol) in toluene (20 mL) was stirred under nitrogen for 30 minutes. Compound 79b (3.8 g, 18.2 mmol) was then added and microwave-treated at 130°C for 30 minutes. The mixture was washed with water and extracted with ethyl acetate. The organic phase was concentrated and separated by column chromatography to afford 79c (1.05 g, 32%) as a brown solid.
[0254] ESI m / z[M+H] + =201.0.
[0255] 2. (Compound 79f)
[0256] Referring to the synthetic route of 70f in Example 18, 79f was synthesized by substituting 79c for 70c via three steps. The isomers of 79f were not separated, and the mixture was used in the next reaction.
[0257] 3. (Compounds 79i, 79i-A, 79i-B)
[0258] Referring to the synthesis conditions of compound 70i-A in Example 18, 79f was used instead of 70f-P1, and a mixture 79i was synthesized through three steps. After chiral resolution (column: IBN, mobile phase: Hex / EtOH 50 / 50, flow rate: 25 mL / min, detection wavelength: 254 nM), white solids 79i-A (isomer A, retention time: 15.494 minutes) and 79i-B (isomer B, retention time: 18.437 minutes) were obtained, both of which were chirally pure compounds. At the same time, two other isomers 79i-C (retention time: 29.632 minutes) and 79i-D (retention time: 35.885 minutes) were also separated and obtained in lower yields.
[0259] 79i-A (isomer A): ESI m / z [M+H] + =488.0. 1 H NMR (400MHz, DMSO-d6) δ8.38(s,1H),8.32(d,J=8.0Hz,1H),7.84(d,J=8.4 Hz,1H),7.72(s,1H),7.69-7.44(m,2H),7.35-7.33(m,2H),7.28-7.25(m, 2H),7.19-7.18(m,1H),6.01(d,J=4.8Hz,1H),5.25-5.23(m,1H),4.98(d, J=4.0Hz,1H),4.89(d,J=16.0Hz,1H),4.37(d,J=16.4Hz,1H),3.74(s,3H).
[0260] 79i-B (isomer B): ESI m / z [M+H] + =488.0. 1 H NMR (400MHz, DMSO-d6) δ8.38 (s, 1H), 8.33-8.31 (m, 1H), 7.84 (d, J = 8.4Hz ,1H),7.72(s,1H),7.69-7.44(m,2H),7.35-7.34(m,2H),7.28-7.25(m,2H ),7.19-7.18(m,1H),6.02(d,J=4.4Hz,1H),5.26-5.23(m,1H),4.98(d,J =4.4Hz,1H),4.89(d,J=16.0Hz,1H),4.37(d,J=16.0Hz,1H),3.74(s,3H).
[0261] Example 21: (Compounds 84j-A, 84j-B, 84j-AA, 84j-AB)
[0262] 1. (Compound 84b)
[0263] To a solution (14 mL) of tert-butyl carbamate (1.09 g, 9.3 mmol) and sodium p-toluenesulfonate (2.5 g, 14.0 mmol) in methanol (7 mL) was slowly added. The mixture was stirred at room temperature for half an hour, and then formic acid (0.72 mL) was added. The mixture was stirred at room temperature for 3 days, and the reaction mixture was filtered. The filter cake was washed with water and dried to afford 84b (1.7 g, 50%) as a white solid.
[0264] 2. (Compound 84e)
[0265] To a solution of compound 84c (125 mg, 4.47 mmol), compound 84b (1.7 g, 4.7 mmol), and compound 84d (226 mg, 0.89 mmol) in tetrahydrofuran (20 mL) was added triethylamine (7.1 g, 70.3 mmol), and the mixture was stirred at 60°C under nitrogen for 16 hours. The reaction mixture was cooled to zero degrees Celsius, treated with saturated ammonium chloride, extracted with ethyl acetate, dried over sodium sulfate, and separated by column chromatography to afford 84e (1.05 g, 70%) as a white solid.
[0266] ESI m / z[M+H] + =332.1.
[0267] 3. (Compound 84f)
[0268] To a solution of compound 84e (1.84 g, 5.55 mmol) in methanol (40 mL) was slowly added sodium borohydride (253 mg, 6.67 mmol) and stirred at zero temperature for 1 hour. Excess sodium borohydride was quenched by adding a small amount of water. The reaction solution was directly concentrated and separated by column chromatography to obtain a yellow solid 84f (1.75 g, 94%).
[0269] ESI m / z[M+H] + =334.1.
[0270] 4. (Compound 84g)
[0271] To a solution of compound 84f (750 mg, 2.25 mmol) in dichloromethane (10 mL) was slowly added trifluoroacetic acid (5 mL) and stirred at room temperature for 1 hour. The reaction solution was directly concentrated to afford 84 g (781 mg, trifluoroacetate) as a yellow oil.
[0272] ESI m / z[M+H] + =234.1.
[0273] 5. (Compounds 84j-A, 84j-B)
[0274] Refer to the synthetic route of compound 20 in Example 1. Compound 84g was substituted for 1d' to obtain 84j. The diastereomers were separated by reverse phase preparative method to obtain white solids 84j-A and 84j-B.
[0275] 84j-A (isomer A):ESI m / z[M+H] + =504.0. 1H NMR (400MHz, DMSO-d6) δ8.60(d,J=4.0Hz,1H),8.36(s,1H),8.30-8.28(m,1H),8.25(s,1H),7.89(d,J=8.0Hz,1H),7.82- 7.78(m,1H),7.72-7.70(m,2H),7.66-7.36(m,2H),7.34-7.32(m,1H),6.03(d,J=6.0Hz,1H),5.52-5.48(m,1H),5.12(d, J=8.8Hz,1H),5.09-4.98(m,2H).
[0276] 84j-B (isomer B):ESI m / z[M+H] + =503.9. 1 H NMR(400MHz,DMSO-d6)δ8.53-8.47(m,2H),8.35-8.33(m,2H),7.93-7.91(m,1H),7.71-7.43(m,4H),7 .27-7.21(m,2H),6.08(d,J=5.2Hz,1H),5.67-5.64(m,1H),5.38(d,J=5.6Hz,1H),5.10-4.99(m,2H).
[0277] 6. (Compounds 84j-AA, 84j-AB)
[0278] Compound 84j-A (100 mg) was subjected to chiral separation (column: IC, mobile phase: Hex / EtOH / TFA 40 / 60 / 0.3, flow rate: 25 mL / min, detection wavelength: 254 nM) to give white solid compounds 84j-AA (retention time: 15.293 minutes, 30 mg, 30%) and compound 84j-AB (retention time: 21.500 minutes, 30 mg, 30%), both of which were chirally pure compounds.
[0279] 84j-AA (isomer AA):ESI m / z[M+H] + =504.0. 1H NMR (400MHz, DMSO-d6) δ8.60(d,J=4.0Hz,1H),8.36(s,1H),8.30-8.28(m,1H),8.25(s,1H),7.88(d,J=8.0Hz,1H),7.82-7.77(m,1H),7.7 2-7.70(m,2H),7.66-7.41(m,2H),7.35-7.32(m,1H),6.03(d,J=6.0Hz,1H),5.52-5.48(m,1H),5.11(d,J=8.4Hz,1H),5.09-4.98(m,2H).
[0280] 84j-AB (isomer AB):ESI m / z[M+H] + =504.0. 1 H NMR (400MHz, DMSO-d6) δ8.60(d,J=4.0Hz,1H),8.36(s,1H),8.30-8.28(m,1H),8.25(s,1H),7.89(d,J=8.0Hz,1H),7.82-7.78 (m,1H),7.72-7.70(m,2H),7.66-7.41(m,2H),7.35-7.32(m,1H),6.03(d,J=6.0Hz,1H),5.52-5.48(m,1H),5.13-4.98(m,3H).
[0281] Example 22: (Compounds 88j-A, 88j-B, 88j-AA, 88j-AB)
[0282] 1. (Compounds 88j-A, 88j-B)
[0283] Refer to the synthetic route of compound 84j in Example 21. 5-Fluoropyridine-2-carboxaldehyde was used instead of 84a, and the diastereomers were separated by reverse phase preparative separation to obtain white solids 88j-A and 88j-B.
[0284] 88j-A (isomer A): ESI m / z [M+H] + =521.9. 1H NMR (400MHz, DMSO-d6) δ8.59(d,J=3.2Hz,1H),8.37(d,J=1.6Hz,1H),8.31-8.29(m,1H),8.26(s,1H),7.88(d,J=8.4Hz,1H) ,7.77-7.70(m,3H),7.67-7.41(m,2H),6.02(d,J=5.6Hz,1H),5.49-5.45(m,1H),5.17(d,J=8.8Hz,1H),5.07-4.96(m,2H).
[0285] 88j-B (isomer B):ESI m / z[M+H] + =522.1. 1 H NMR (400MHz, DMSO-d6) δ8.51(d,J=3.2Hz,1H),8.47(d,J=2.8Hz,1H),8.36-8.34(m,2H),7.94(d,J=8.4Hz,1H),7.69 -7.43(m,4H),7.35-7.32(m,1H),6.10(d,J=5.2Hz,1H),5.62-5.59(m,1H),5.42(d,J=6.0Hz,1H),5.09-4.99(m,2H).
[0286] 2. (Compounds 88j-AA, 88j-AB)
[0287] Compound 88j-A (100 mg) was subjected to chiral separation (column: IC, mobile phase: Hex / EtOH / TFA 40 / 60 / 0.3, flow rate: 25 mL / min, detection wavelength: 254 nM) to afford white solid compounds 88j-AA (retention time: 10.727 minutes, 30 mg, 30%) and 88j-AB (retention time: 17.608 minutes, 20 mg, 20%), both of which were chirally pure.
[0288] 88j-AA (isomer AA):ESI m / z[M+H] + =521.9. 1H NMR (400MHz, DMSO-d6) δ8.59(d,J=2.8Hz,1H),8.37(d,J=1.6Hz,1H),8.31-8.29(m,1H),8.25(s,1H),7.88(d,J=8.4Hz,1H) ,7.76-7.69(m,3H),7.66-7.41(m,2H),6.01(d,J=5.6Hz,1H),5.48-5.44(m,1H),5.16(d,J=8.4Hz,1H),5.06-4.95(m,2H).
[0289] 88j-AB (isomer AB):ESI m / z[M+H] + =521.9. 1 H NMR (400MHz, DMSO-d6) δ8.59(d,J=2.4Hz,1H),8.37(s,1H),8.31-8.29(m,1H),8.25(s,1H),7.88(d,J=8.0Hz,1H),7.7 6-7.69(m,3H),7.66-7.41(m,2H),6.02(d,J=6.0Hz,1H),5.48-5.44(m,1H),5.17(d,J=8.4Hz,1H),5.06-4.95(m,2H).
[0290] Example 23: (Compound 92)
[0291] Referring to the synthesis method of compound 4 in Example 4, methyl chloroformate was used instead of cyclopropylsulfonyl chloride to obtain white solid 92.
[0292] ESI m / z[M+H] + =443.1. 1 H NMR (400MHz, DMSO-d6) δ8.38-8.34(m,2H),7.98(d,J=4Hz,1H),7.57(t,1H),7.03(d,J=4.2Hz,1H),4 .68(s,1H),3.50-3.45(m,2H)3.31(s,3H),1.89-1.70(m,5H),1.51-1.49(m,1H),1.28-1.24(m,2H).
[0293] Example 24: (Compound 93)
[0294] Referring to the synthesis method of compound 4 in Example 4, dimethylaminoformyl chloride was used instead of cyclopropylsulfonyl chloride to obtain white solid 93.
[0295] ESI m / z[M+H] + =456.1. 1 H NMR (400MHz, DMSO-d6) δ8.37-8.33(m,2H),7.87(d,J=4Hz,1H),7.57(t,1H),5.99(d,J=3.6Hz,1H),4.65(s,1H ),3.76-3.73(m,1H),3.57-3.56(m,1H),2.63(s,6H),1.85-1.70(m,5H),1.55-1.52(m,1H),1.30-1.24(m,2H).
[0296] Example 25: (Compound 94)
[0297] Referring to the synthesis method of compound 4 in Example 4, methylaminoformyl chloride was used instead of cyclopropylsulfonyl chloride to obtain white solid 94.
[0298] ESI m / z[M+H] + =442.1. 1 H NMR (400MHz, DMSO-d6) δ8.39-8.35(m,2H),7.91(d,J=8Hz,1H),7.59(t,1H),5.77(d,J=12Hz,1H),4.64(d,J=5.2Hz,1H),4.71(dd ,J=10Hz,2H),3.76-3.73(m,1H),3.45-3.37(m,1H),2.39(d,J=6Hz,3H),1.91-1.88(m,2H),1.75-1.72(m,3H),1.34-1.30(m,3H).
[0299] Example 26: (Compounds 95j-A, 95j-B, 95j-BA, 95j-BB)
[0300] 1. (Compounds 95j-A, 95j-B)
[0301] Refer to the synthetic route of compound 84j in Example 21. 1-Methylpyrazole-4-carboxaldehyde was used instead of 84a and 84c to give 95j. The diastereomers were separated by reverse phase preparative method to give white solids 95j-A and 95j-B.
[0302] 95j-A (isomer A): ESI m / z [M+H] + =492.0. 1H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.34(dd,J1=1.2Hz,J2=8.0Hz,1H),7.73(d,J=8.0Hz,1H),7.70(s,1H),7.60(s,1H),7.56(s,1H),7 .46(s,1H),7.36-7.10(m,1H),5.52(d,J=6.0Hz,1H),5.04(d,J=6.0Hz,1H),4.83(d,J=6.0Hz,1H),4.45(d,J=15.6Hz,1H),3.81(s,6H).
[0303] 95j-B (isomer B): ESI m / z [M+H] + =492.0. 1 H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.34(dd,J1=1.2Hz,J2=8.0Hz,1H),7.78(s,1H),7.72(d,J=8.0Hz,1H),7.64(s,1H),7.49(s,1H),7.36(s ,1H),7.35-7.10(m,1H),5.34(d,J=5.2Hz,1H),5.03(d,J=5.2Hz,1H),4 .77(d,J=5.2Hz,1H),4.39(d,J=15.6Hz,1H),3.84(s,3H),3.79(s,3H).
[0304] 2. (Compounds 95j-BA, 95j-BB)
[0305] Compound 95j-B (40 mg) was subjected to chiral separation (column: IE, mobile phase: MeOH / EtOH 50 / 50, flow rate: 25 mL / min, detection wavelength: 214 nM) to give white solid compounds 95j-BA (retention time: 12.459 minutes, 20 mg, 50%) and compound 95j-BB (retention time: 15.560 minutes, 20 mg, 50%), both of which were chirally pure compounds.
[0306] 95j-BA (isomer BA): ESI m / z [M+H] + =492.0. 1H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.34(dd,J1=1.6Hz,J2=8.4Hz,1H),7.78(s,1H),7.72(d,J=8.0Hz,1H),7.64(s,1H),7.49(s,1H),7.36(s ,1H),7.35-7.10(m,1H),5.34(d,J=4.8Hz,1H),5.04(d,J=4.8Hz,1H),4 .80(d,J=4.8Hz,1H),4.39(d,J=15.6Hz,1H),3.85(s,3H),3.79(s,3H).
[0307] 95j-BB (isomer BB):ESI m / z[M+H] + =492.0. 1 H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.34(dd,J1=1.6Hz,J2=8.4Hz,1H),7.78(s,1H),7.72(d,J=8.4Hz,1H),7.64(s,1H),7.49(s,1H),7.36(s ,1H),7.35-7.10(m,1H),5.34(d,J=4.8Hz,1H),5.03(d,J=4.8Hz,1H),4 .78(d,J=4.8Hz,1H),4.40(d,J=15.6Hz,1H),3.85(s,3H),3.79(s,3H).
[0308] Example 27: (Compounds 99j-A, 99j-B, 99j-AA, 99j-AB)
[0309] 1. (Compounds 99j-A, 99j-B)
[0310] Refer to the synthetic route of compound 84j in Example 21. 2-Pyrazinecarboxaldehyde was used instead of 84a and 84c, and the diastereomers were separated by reverse phase preparative separation to give white solids 99j-A and 99j-B.
[0311] 99j-A (isomer A): ESI m / z [M+H] + =488.1. 1H NMR (400MHz, DMSO-d6) δ8.92(s,1H),8.83(d,J=1.2Hz,1H),8.70(s,1H),8.63(d,J=2.4Hz,1H),8.52-8.48(m,2H),8.32-8.30(m,1H) ,8.26(s,1H),7.88(d,J=8.4Hz,1H),7.66-7.41(m,1H),6.24(d,J=5.6Hz,1H),5.54-5.50(m,1H),5.36(d,J=9.2Hz,1H),5.03(s,2H).
[0312] 99j-B (isomer B): ESI m / z [M+H] + =488.1. 1 H NMR(400MHz, DMSO-d6)δ8.81(s,J=1.2Hz,1H),8.64(d,J=1.2Hz,1H),8.59-8.50(m,4H),8.37-8.35(m,2H),7.93(d, J=8.4Hz,1H),7.68-7.43(m,1H),6.39(d,J=5.2Hz,1H),5.73-5.70(m,1H),5.56(d,J=5.6Hz,1H),5.15-5.05(s,2H).
[0313] 2.(Compound 99j-AA, 99j-AB)
[0314] Compound 99j-A (100 mg) was subjected to chiral separation (column: IH, mobile phase: MeOH / EtOH / TFA 50 / 50 / 0.3, flow rate: 25 mL / min, detection wavelength: 254 nM) to give white solid compounds 99j-AA (retention time: 8.371 minutes, 35 mg, 35%) and compound 99j-AB (retention time: 11.741 minutes, 35 mg, 35%), both of which were chirally pure compounds.
[0315] 99j-AA (isomer AA):ESI m / z[M+H] + =488.0. 1H NMR (400MHz, DMSO-d6) δ8.92(d,J=1.2Hz,1H),8.83(d,J=1.2Hz,1H),8.70(s,1H),8.63(d,J=2.4Hz,1H),8.52-8.48(m,2H),8.32-8 .26(m,2H),7.88(d,J=8.0Hz,1H),7.66-7.41(m,1H),6.24(d,J=6.0Hz,1H),5.54-5.51(m,1H),5.36(d,J=9.2Hz,1H),5.03(s,2H).
[0316] 99j-AB (isomer AB):ESI m / z[M+H] + =488.0. 1 H NMR (400MHz, DMSO-d6) δ8.93(s,1H),8.83(d,J=0.8Hz,1H),8.70(d,J=2.0Hz,1H),8.63(d,J=2.4Hz,1H),8.52-8.48(m,2H),8.32-8 .26(m,2H),7.88(d,J=8.4Hz,1H),7.66-7.41(m,1H),6.25(d,J=6.0Hz,1H),5.55-5.51(m,1H),5.36(d,J=9.2Hz,1H),5.04(s,2H).
[0317] Example 28: (Compounds 103j-A, 103j-B, 103j-C, 103j-D)
[0318] Refer to the synthetic route of compound 84j in Example 21. 2-Pyrimidinecarboxaldehyde was used instead of 84a and 84c, and the resulting mixture 103j was subjected to chiral resolution (column: IBN, mobile phase: MeOH / DCM 90 / 10, flow rate: 25 mL / min, detection wavelength: 254 nM) to afford white solid compounds 103j-A (retention time: 9.214 minutes), 103j-B (retention time: 12.041 minutes), 103j-C (retention time: 13.807 minutes), and 103j-D (retention time: 18.648 minutes), all of which were chirally pure compounds.
[0319] 103j-A (isomer A): ESI m / z [M+H] + =488.0. 1H NMR (400MHz, DMSO-d6) δ8.78-8.75(m,4H),8.36-8.34(m,1H),8.31(s,1H),7.97(d,J=8.4Hz,1H),7.68-7.43( m,1H),7.41-7.36(m,2H),5.94(d,J=4.8Hz,1H),5.73-5.71(m,1H),5.53-5.48(m,2H),5.14(d,J=16.4Hz,1H).
[0320] 103j-B (isomer B):ESI m / z[M+H] + =488.0. 1 H NMR (400MHz, DMSO-d6) δ8.82-8.76(m,4H),8.32-8.30(m,1H),8.25(s,1H),7.94(d,J=8.0Hz,1H),7.67 -7.38(m,3H),5.86(d,J=6.0Hz,1H),5.51-5.42(m,2H),5.33(d,J=16.0Hz,1H),5.06(d,J=15.6Hz,1H).
[0321] 103j-C (isomer C):ESI m / z[M+H] + =487.9. 1 H NMR (400MHz, DMSO-d6) δ8.82-8.77(m,4H),8.31(d,J=8.4Hz,1H),8.25(s,1H),7.94(d,J=8.0Hz,1H),7.6 7-7.38(m,3H),5.86(d,J=6.4Hz,1H),5.51-5.42(m,2H),5.33(d,J=16.0Hz,1H),5.06(d,J=15.6Hz,1H).
[0322] 103j-D (isomer D):ESI m / z[M+H] + =488.0. 1 H NMR (400MHz, DMSO-d6) δ8.78-8.75(m,4H),8.36-8.34(m,1H),8.31(s,1H),7.97(d,J=8.0Hz,1H),7.68-7.43( m,1H),7.41-7.36(m,2H),5.95(d,J=4.8Hz,1H),5.73-5.71(m,1H),5.53-5.47(m,2H),5.13(d,J=16.4Hz,1H).
[0323] Example 29: (Compound 107)
[0324] Referring to the synthesis method of compound 108 in Example 1, (S)-N-Boc-3-aminomethylmorpholine was used instead of 1d' to obtain white solid 107.
[0325] ESI m / z[MH] - =387.1. 1 H NMR (400MHz, Methanol-d4) δ8.56(s,1H),8.47(dd,J=8.1,1.6Hz,1H),7.87(d,J=8.1Hz,1H),7.29(t,J=51.6Hz,1H),4.75(d,J=15.0Hz,1H),4.63( d,J=14.9Hz,1H),4.04(d,J=11.0Hz,1H),3.92(dt,J=12.2,3.2Hz,1H),3 .69(ddd,J=12.3,10.0,2.8Hz,1H),3.55-3.36(m,4H),3.22-2.95(m,2H).
[0326] Example 30: (Compound 109)
[0327] To a mixture of cyclopropylamine (500 mg, 8.76 mmol) and triethylamine (2.66 g, 26.28 mmol) in toluene (3 mL) and water (2 mL) was added triphosgene (0.91 g, 3.07 mmol) at 0°C and stirred for 2 hours. The upper toluene phase was removed and added to a solution of compound 108 (200 mg, 0.52 mmol) and triethylamine (130 mg, 1.3 mmol) in N,N-dimethylformamide (2 mL) and stirred for 2 hours. The reaction mixture was washed with water and separated by reverse-phase column chromatography to afford compound 109 (30 mg, 12%) as a white solid.
[0328] ESI m / z[M+H] + =468.2. 1H NMR (400MHz, DMSO-d6) δ8.41(d,J=1.5Hz,1H),8.37(dd,J=8.1,1.6Hz,1H),7.91(d,J=8.1Hz,1H),7.60(t,J=51. 3Hz,1H),6.08(s,1H),5.75(d,J=9.1Hz,1H),4.80(d,J=15.5Hz,1H),4.66(d,J=15.5Hz,1H),3.73(d,J=11.1Hz,1 H),3.52(t,J=10.2Hz,1H),2.23(dd,J=7.0,4.0Hz,1H),2.09-1.99(m,1H),1.92(d,J=13.1Hz,2H),1.75(d,J=11 .0Hz,2H),1.48(d,J=11.7Hz,2H),0.46(dt,J=12.4,7.5Hz,2H),0.24(dd,J=10.0,5.0Hz,1H),0.18-0.08(m,1H).
[0329] Example 31: (Compound 110)
[0330] Referring to the synthesis method of compound 109 in Example 30, cyclopropylmethylamine was used instead of cyclopropylamine to obtain white solid 110.
[0331] ESI m / z[M+H] + =482.2. 1 H NMR(400MHz, DMSO-d6)δ8.44-8.20(m,2H),7.88(d,J=8.1Hz,1H),7.57(t,J=51.3Hz,1H), 5.85-5.68(m,2H),4.78(d,J=15.4Hz,1H),4.62(d,J=15.5Hz,1H),3.79-3.59(m,1H),2.69 (td,J=6.3,4.7Hz,2H),1.88(d,J=11.7Hz,2H),1.71(q,J=12.0,10.9Hz,3H),1.45-1.19( m,4H),0.64-0.53(m,1H),0.10(ddd,J=9.8,4.7,2.7Hz,2H),-0.09(dd,J=4.8,1.9Hz,2H).
[0332] Example 32: (Compound 111)
[0333] Referring to the synthesis method of compound 109 in Example 30, trifluoroethylamine was used instead of cyclopropylamine to obtain white solid 111.
[0334] ESI m / z[M+H] + =510.2. 1 H NMR (400MHz, DMSO-d6) δ8.41 (s, 1H), 8.38 (dd, J=8.1, 1.6Hz, 1H), 7.92 (d, J= 8.1Hz,1H),7.62(t,J=51.3Hz,1H),6.44(t,J=6.5Hz,1H),6.13(d,J=9.3Hz, 1H),4.82-4.64(m,2H),3.85-3.73(m,1H),3.72-3.62(m,2H),3.47(dt,J=11 .1,5.7Hz,1H),1.99-1.88(m,2H),1.76(t,J=12.3Hz,3H),1.50-1.30(m,3H).
[0335] Example 33: (Compound 112)
[0336] Referring to the synthesis method of compound 109 in Example 30, tetrahydropyrrole was used instead of cyclopropylamine to obtain white solid 112.
[0337] ESI m / z[M+H] + =482.3. 1 H NMR (400MHz, DMSO-d6) δ8.40(d,J=1.5Hz,1H),8.36(dd,J=8.1,1.6Hz,1H),7.90(d,J=8.1Hz,1H),7.6 0(t,J=51.3Hz,1H),5.81(d,J=9.0Hz,1H),4.70(q,J=15.6Hz,2H),3.75(t,J=11.9Hz,1H),3.59(td,J =11.1,10.7,3.8Hz,1H),3.12(dt,J=9.4,6.1Hz,2H),3.01(dt,J=9.4,6.3Hz,2H),1.87(t,J=10.4Hz, 2H),1.74(q,J=11.3,10.1Hz,3H),1.69-1.62(m,4H),1.56(d,J=12.2Hz,1H),1.33(t,J=10.5Hz,2H).
[0338] Example 34: (Compound 113)
[0339] Referring to the synthesis method of compound 109 in Example 30, morpholine was used instead of cyclopropylamine to obtain white solid 113.
[0340] ESI m / z[M+H] + =498.2. 1 H NMR (400MHz, DMSO-d6) δ8.60-8.30(m,2H),7.82(d,J=8.2Hz,1H),7.26(t,J=51.6Hz,1H),6.28(d,J=8.9Hz,1H),4.73-4.60(m,2H),3.98-3.80(m,1 H),3.63(td,J=11.2,4.1Hz,1H),3.51-3.36(m,4H),3.23(t,J=5.0Hz,4H) ,2.01(d,J=13.8Hz,2H),1.93-1.70(m,3H),1.48(q,J=13.8,13.2Hz,3H).
[0341] Example 35: (Compound 114)
[0342] To a solution of cyclopropylcarboxylic acid (20 mg, 0.23 mmol) in N,N-dimethylformamide (2 mL) was added diisopropylethylamine (90 mg, 0.70 mmol) and HATU (90 mg, 0.24 mmol). The mixture was stirred at room temperature for 30 minutes, followed by the addition of compound 108 (100 mg, 0.26 mmol) and stirring overnight. The reaction mixture was filtered and separated by reverse phase column chromatography to afford 114 (30 mg, 28%) as a white solid.
[0343] ESI m / z[M+H] + =453.2. 1 H NMR (400MHz, DMSO-d6) δ8.44-8.31(m,2H),7.98(d,J=9.4Hz,1H),7.89(d,J=8.1Hz, 1H),7.60(t,J=51.3Hz,1H),4.80-4.53(m,2H),4.00-3.82(m,1H),3.49(dd,J=11.3 ,3.8Hz,1H),1.98-1.82(m,2H),1.82-1.67(m,3H),1.59-1.21(m,4H),0.54(dddd,J =20.3,10.0,7.3,3.3Hz,2H),0.46-0.32(m,1H),0.20(ddt,J=9.8,7.2,3.9Hz,1H).
[0344] Example 36: (Compound 118)
[0345] Referring to the synthesis method of Example 21, 118 was obtained by replacing 84a with 118a and replacing 84c with 118c.
[0346] ESI m / z[M+H] + =506.1. 1 H NMR (400MHz, DMSO-d6) δ8.40(s,1H),8.35(dd,J=8.1,1.6Hz,1H),7.87(d,J=8.1Hz,1H),7.73(d,J=13.3Hz,1H),7.47(d,J=7.0Hz,1H),7.41(dd ,J=8.5,5.5Hz,2H),7.11(t,J=8.8Hz,2H),6.09(d,J=4.9Hz,1H),5.26( t,J=5.1Hz,1H),5.06–4.83(m,2H),4.40(d,J=16.2Hz,1H),3.79(s,3H).
[0347] Example 37: (Compound 116)
[0348] Refer to the synthesis method of compound 2 in Example 2. Trifluoromethanesulfonic anhydride was used instead of difluoroacetic anhydride to obtain white solid 116.
[0349] ESI m / z[M+H] + =515.2. 1 H NMR (400MHz, DMSO-d6) δ9.36(d,J=9.1Hz,1H),8.46-8.33(m,2H),7.93(d,J=8.1Hz,1H),7.60(t,J=51.3Hz,1H),4.73(d,J=15.5Hz,1H) ,4.63(d,J=15.4Hz,1H),4.03-3.90(m,1H),3.69-3.59(m,1H),1.82(d,J=17.0Hz,4H),1.73(d,J=11.0Hz,2H),1.36(d,J=10.4Hz,2H).
[0350] Example 38: (Compound 117)
[0351] Referring to the synthesis method of compound 72 in Example 19, 2-bromopyridine was used instead of 4-bromo-1-methyl-1H-pyrazole in the first step to obtain white solid 117.
[0352] ESI m / z[M+H] + =441.2. 1H NMR (400MHz, DMSO-d6) δ8.60(d,J=4.9Hz,1H),8.47(d,J=1.4Hz,1H),8.41(dd,J=8.1,1.6Hz,1H),7.90(d,J=8.2Hz ,1H),7.80-7.74(m,4H),7.69-7.64(m,2H),7.54(d,J=51.2Hz,1H),7.32(ddd,J=6.7,4.8,1.7Hz,1H),4.98(s,2H).
[0353] Example 39: (Compound 14)
[0354] 1. (Compound 14e)
[0355] Referring to the synthesis method of compound 108 in Example 1, 14a was used instead of 1d', and white solid amine 14e was synthesized through four steps.
[0356] 2. (Compound 14)
[0357] Referring to the synthesis method of compound 2 in Example 2, compound 14e was used instead of compound 108 to obtain white solid 14.
[0358] ESI m / z[MH] - =463.2. 1 H NMR (400MHz, DMSO-d6) δ8.54(s,1H),8.47(dd,J=8.1,1.6Hz,1H),7.88(d,J=8.1Hz,1H),7.32(t,J=51.7Hz,1H),5.95(td,J=54.0,3.3Hz,1H ),4.66(s,2H),4.43(dt,J=10.5,5.5Hz,1H),4.13-4.05(m,2H),3.89-3.77(m,2H),3.65-3.58(m,1H),2.05(ddd,J=18.9,12.2,6.6Hz,3H).
[0359] Example 40: (Compound 13)
[0360] 1. (Compound 13a)
[0361] To a solution of compound 14a (200 mg, 0.92 mmol) in dichloromethane (2 mL) was added diisopropylethylamine (360 mg, 2.76 mmol). The mixture was stirred for five minutes, and difluoroacetic anhydride (240 mg, 1.38 mmol) was added dropwise at 0°C. The mixture was stirred for two hours. The reaction mixture was treated with water, extracted with ethyl acetate, and concentrated to afford 13a (250 mg, 91%) as a colorless oil.
[0362] ESI m / z[M+H] + =295.1.
[0363] 2. (Compound 13b)
[0364] To a solution of compound 13a (250 mg, 0.85 mmol) in dichloromethane was added a solution of hydrogen chloride in dioxane (1 mL, 4 M). The mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated to obtain a colorless oil 13b (150 mg, 90%).
[0365] ESI m / z[M+H] + =195.1.
[0366] 3. (Compound 13)
[0367] Refer to the synthesis method of compound 20 in Example 1. Substituting 13b for 1d', 13 was obtained as a white solid.
[0368] ESI m / z[MH] - =463.2. 1 H NMR (400MHz, Methanol-d4) δ8.54(s,1H),8.47(dd,J=8.1,1.6Hz,1H),7.88(d,J=8.1Hz,1H),7.32(t,J=51.7Hz,1H),5.95(td,J=54.0,3.3Hz, 1H),4.66(s,2H),4.43(dt,J=10.5,5.5Hz,1H),4.13–4.05(m,2H),3.8 9–3.77(m,2H),3.65–3.58(m,1H),2.05(ddd,J=18.9,12.2,6.6Hz,3H).
[0369] Example 41: (Compound 65)
[0370] Referring to the synthesis method of compound 114 in Example 35, compound 14e was used instead of compound 108, and 1-trifluoromethylcyclopropyl-1-carboxylic acid was used instead of cyclopropylcarboxylic acid to obtain white solid 65.
[0371] ESI m / z[M+H]+ =521.2. 1 H NMR (400MHz, DMSO-d6) δ8.45(d,J=1.5Hz,1H),8.39(dd,J=8.1,1.6Hz,1H),7.92(d,J=8.2Hz,1H),7 .82(d,J=9.1Hz,1H),7.59(t,J=51.3Hz,1H),4.77-4.63(m,2H),4.25(dq,J=10.2,5.3Hz,1H),3.87 (ddd,J=14.5,10.6,4.0Hz,2H),3.75-3.59(m,2H),3.46(d,J=10.3Hz,1H),2.06-1.85(m,1H),1.81 (dd,J=13.5,4.6Hz,1H),1.41-1.32(m,1H),1.19-1.12(m,1H),1.08(ddd,J=10.4,8.7,6.4Hz,2H).
[0372] Example 42: (Compound 66)
[0373] Referring to the synthesis method of compound 2 in Example 2, compound 14e was used instead of compound 108, and pentafluoropropionic anhydride was used instead of difluoroacetic anhydride to obtain white solid 66.
[0374] ESI m / z[M+H] + =533.0. 1 H NMR (400MHz, DMSO-d6) δ9.63(s,1H),8.46(s,1H),8.40(dd,J=8.1,1.6Hz,1H),7.94(d,J=8.2Hz,1H),7.60(d,J=102.6Hz,1H),7.60(s,1H),4.8 0-4.62(m,2H),4.36(s,1H),3.91(dd,J=10.2,4.6Hz,2H),3.84-3.67(m ,2H),3.50(t,J=11.7Hz,1H),2.06-1.99(m,1H),1.89(d,J=10.9Hz,1H).
[0375] Example 43: (Compound 119)
[0376] Referring to the synthesis method of compound 72 in Example 19, 4-bromo-1-fluorobenzene was used instead of 4-bromo-1-methyl-1H-pyrazole in the first step to obtain white solid 119. ESI m / z [MH] - =456.2
[0377] 1 H NMR (400MHz, DMSO-d6) δ8.52(d,J=1.5Hz,1H),8.38(dd,J=8.1,1.6Hz,1H),7.84–7.78(m,2H),7.73–7.48(m,6H),7.24–7.18(m,2H),4.66(s,2H).
[0378] Example 44: (Compound 120)
[0379] Referring to the synthesis method of compound 72 in Example 19, 3-bromo-1-fluorobenzene was used instead of 4-bromo-1-methyl-1H-pyrazole in the first step to obtain 120 as a white solid.
[0380] 1 H NMR(400MHz, DMSO-d6)δ8.54(d,J=1.5Hz,1H),8.39(dd,J=8.1,1.6Hz,1H),7.85–7.78(m, 2H),7.67–7.47(m,4H),7.44–7.37(m,3H),7.18(tdd,J=9.2,4.0,2.2Hz,1H),4.68(s,2H).
[0381] Example 45: (Compound 121)
[0382] Referring to the synthesis method of compound 72 in Example 19, 5-bromo-1,3-difluorobenzene was used instead of 4-bromo-1-methyl-1H-pyrazole in the first step to obtain white solid 121.
[0383] 1 H NMR (400MHz, DMSO-d6) δ8.54(d,J=1.5Hz,1H),8.41(dd,J=8.1,1.6Hz,1H),7.86(d,J=8.2Hz,1H), 7.83–7.78(m,1H),7.75–7.46(m,4H),7.33–7.26(m,2H),7.23(tt,J=9.4,2.4Hz,1H),4.78(s,2H).
[0384] Example 46: (Compound 63)
[0385] 1. (Compound 63b)
[0386] Compound 63a (5 g, 27.75 mmol), cuprous bromide (4.78 g, 33.3 mmol), and acetonitrile (100 mL) were added to the reaction flask. The temperature was lowered to 0°C, and tert-butyl nitrite (7.73 g, 74.93 mmol) was added dropwise. The mixture was stirred at room temperature for two days. LCMS indicated that the reaction was complete. The reaction solution was concentrated and passed through a silica gel column (dichloromethane / ethyl acetate: 20-50%) to afford product 63b (5 g, 73.83%) as an off-white solid. MS m / z [M+H] + :244.0.
[0387] 2. (Compound 63c)
[0388] Compound 63b (1.5 g, 6.15 mmol), azobisisobutyronitrile (0.1 g, 0.62 mmol), N-bromosuccinimide (1.09 g, 6.15 mmol), and dichloroethane (20 mL) were added to the reaction flask. The temperature was raised to 80°C and stirred overnight. LCMS showed that the reaction was complete. The reaction solution was concentrated and purified on a silica gel column (dichloromethane / ethyl acetate: 30-80%) to give the product 63c (1.2 g, 60.46%) as a yellow oil. MS m / z [M+H] + :323.8
[0389] 3. (Compound 63d)
[0390] Compound 63c (1.2 g, 4.03 mmol), compound 1d' (1 g, 4.67 mmol), and acetonitrile (20 mL) were added to the reaction flask. Stirring was carried out at room temperature for 5 hours. LCMS indicated the reaction was complete. Water (30 mL) was added to the reaction solution, and extraction with dichloromethane (30 mL x 2) was performed. The mixture was separated, washed with water and saturated brine, dried over sodium sulfate, concentrated, and purified on a silica gel column (dichloromethane / ethyl acetate: 50-90%) to obtain an off-white product 63d (1 g, yield: 54.44%). MS m / z [M+H] + :456.2.
[0391] 4. (Compound 63e)
[0392] Compound 63d (1 g, 2.19 mmol), benzyl mercaptan (0.5 g, 4.03 mmol), N,N-diisopropylethylamine (0.8 g, 6.19 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.13 g, 0.22 mmol), tris(dibenzylideneacetone)dipalladium (0.20 g, 0.22 mmol), and dioxane (20 mL) were added to the reaction flask. After nitrogen substitution three times, the temperature was raised to 106°C and stirred for 16 hours. LCMS showed that the reaction was complete. The reaction solution was purified by silica gel column chromatography (dichloromethane / ethyl acetate: 50-90%) to obtain the off-white product 63e (400 mg, yield: 36.53%). MS m / z [M+H] + :500.3.
[0393] 5. (Compound 63f)
[0394] Compound 63e (400 mg, 0.80 mmol), N-chlorosuccinimide (1070 mg, 8 mmol), acetic acid (3 mL), and water (1 mL) were added to the reaction flask. Stirring was continued at room temperature for 3 hours. LCMS indicated that the reaction was complete. Water (20 mL) was added to the reaction solution, and the pH was adjusted to 7-8 with saturated sodium carbonate solution. The solution was extracted with dichloromethane (30 mL x 2), separated, washed with water, washed with saturated brine, concentrated, and separated on a silica gel column (ethyl acetate / dichloromethane: 30-80%) to give an off-white product 63f (300 mg, yield: 85.26%). MS m / z [M-100] + :340.1.
[0395] 6. (Compound 63g)
[0396] Compound 63f (300 mg, 0.68 mmol), hydrazine hydrate (0.5 mL), and ethanol (5 mL) were added to the reaction flask. The mixture was heated to 80°C and stirred for 2 hours. LCMS indicated that the reaction was complete. The reaction solution was concentrated to obtain a crude product (63 g), which was used directly in the next step (0.3 g, yield: 100%). MS m / z [M-100] + :326.1
[0397] 7. (Compound 63h)
[0398] Compound 63g (300 mg, 0.71 mmol), triethylamine (220 mg, 2.17 mmol), and dichloromethane (5 mL) were added to the reaction flask. Difluoroacetic anhydride (250 mg, 1.44 mmol) was added dropwise at 0°C and stirred for 2 hours. LCMS indicated the reaction was complete. The reaction solution was concentrated to afford the pale yellow product 63h (0.3 g, yield: 84.51%). MS m / z [M-100] +:404.2.
[0399] 8. (Compound 63i)
[0400] Compound 63h (300 mg, 0.60 mmol), p-toluenesulfonyl chloride (140 mg, 0.72 mmol), triethylamine (180 mg, 1.80 mmol), and acetonitrile (5 mL) were added to the reaction flask at 0°C. The mixture was stirred at 25°C for 2 hours. LCMS showed that the reaction was complete. Water (20 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (30 mL*2). The mixture was separated, washed with water, concentrated, and purified on a silica gel column (ethyl acetate / dichloromethane: 40-90%) to give the yellow product 63i (0.1 g, yield: 34.57%). MS m / z [M-100] + :386.1.
[0401] 9. (Compound 63j)
[0402] Compound 63i (100 mg, 0.21 mmol) and dichloromethane (2 mL) were added to the reaction flask. Trifluoroacetic acid (0.2 mL) was added dropwise at 0°C and stirred at room temperature for 1 hour. LCMS indicated the reaction was complete. Water (10 mL) was added to the reaction solution, and the pH was adjusted to 7-9 with saturated aqueous sodium carbonate. The solution was extracted with dichloromethane (30 mL x 2), separated, washed with water, dried over sodium sulfate, filtered, and concentrated to afford the white product 63j (60 mg, yield: 75.59%). MS m / z [M+H] + :386.1.
[0403] 10. (Compound 63)
[0404] To the reaction flask, add 2,2-difluoropropionic acid (400 mg, 3.63 mmol), a drop of DMF, and dichloromethane (3 mL). Slowly add thionyl chloride (450 mg, 3.78 mmol) and stir at 0°C for 2 hours to obtain a 2,2-difluoropropionyl chloride solution.
[0405] To another reaction flask, compound 63j (60 mg, 0.16 mmol), potassium carbonate (100 mg, 0.72 mmol), DCM (3 mL), and water (1 mL) were added. The above 2,2-difluoropropionyl chloride solution was added dropwise at 0°C and stirred at room temperature for 1 hour. LCMS showed that the reaction was complete. The reaction solution was concentrated and purified by reverse phase column (acetonitrile / 0.05% formic acid in water: 30-60%) to obtain product 63 as a white solid (19.2 mg, yield: 25.83%, purity: 96.92%). MS m / z [M+H] + :478.1.
[0406] 1H NMR (400MHz, DMSO-d6) δ9.51(d,J=2.0Hz,1H),9.03(d,J=2.0Hz,1H),8.64(d,J=9.2Hz,1H),7.63(t,J=51.2Hz,1H) ,4.90–4.68(m,2H),4.05–3.90(m,1H),3.77–3.65(m,1H),1.91–1.70(m,6H),1.53(t,J=19.5Hz,3H),1.36(s,2H).
[0407] Example 47: (Compound 145)
[0408] Pentafluoropropionic acid (20 mg, 0.12 mmol), N,N-diisopropylethylamine (30 mg, 0.23 mmol), HATU (44 mg, 0.12 mmol), and DMF (2 mL) were added to the reaction flask. After stirring at room temperature for half an hour, compound 63j (30 mg, 0.078 mmol) was added and stirred at room temperature for 2 hours. LCMS showed that the reaction was complete. The reaction solution was purified by reverse phase column (acetonitrile / 0.05% formic acid in water: 50-70%) to obtain the product 145 as a white solid (2 mg, yield: 4.83%). MS m / z [MH] + :530.2.
[0409] 1 H NMR (400MHz, Methanol-d4) δ9.55(d,J=2.0Hz,1H),8.92(d,J=2.0Hz,1H),7.30(t,J=51.6Hz,1H),4.78(d,J=16.2H z,2H),4.15(td,J=11.2,4.4Hz,1H),3.81(dt,J=13.0,6.6Hz,1H),2.16–1.84(m,6H),1.50(q,J=11.6,11.1Hz,2H).
[0410] Example 48: (Compound 18)
[0411] Compound 63j (30 mg, 0.078 mmol), N,N-diisopropylethylamine (30 mg, 0.039 mmol), and DCM (3 mL) were added to the reaction flask. Difluoroacetic anhydride (16 mg, 0.094 mmol) was added dropwise at 0°C and stirred at room temperature for 1 hour. LCMS showed that the reaction was complete. The reaction solution was concentrated and purified by reverse phase column (acetonitrile / 0.05% formic acid in water: 30-60%) to give the product 18 as a white solid (16.6 mg, yield: 46.02%, purity: 100%). MS m / z [M+H] + :464.2.
[0412] 1 H NMR (400MHz, DMSO-d6) δ9.51(d,J=1.9Hz,1H),9.02(d,J=1.9Hz,1H),8.79(d,J=9.2Hz,1H),7.63(t,J=51.2Hz,1H),6.03(t,J=53.8Hz,1H) ,4.78(q,J=16.1Hz,2H),3.99(d,J=10.4Hz,1H),3.66(td,J=10.4,5.5Hz,1H),2.02–1.77(m,4H),1.77–1.62(m,2H),1.38(d,J=9.7Hz,2H).
[0413] Example 49: (Compound 159)
[0414] 1. (Compound 159a)
[0415] Compound 63c (200 mg, 0.62 mmol), cyclopentylamine (60 mg, 0.64 mmol), potassium carbonate (260 mg, 1.86 mmol), and acetonitrile (2 mL) were added to the reaction flask. The mixture was stirred at room temperature for 3 hours. LCMS indicated that the reaction was complete. Water (30 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (30 mL x 2). The mixture was separated, washed with water and saturated brine, dried over sodium sulfate, filtered, and concentrated to afford the product 159a as a yellow oil (0.1 g, yield: 49.35%). MS m / z [M+H] + :327.0.
[0416] 2. (Compound 159b)
[0417] Compound 159a (0.1 g, 0.31 mmol), benzyl mercaptan (0.06 g, 0.46 mmol), N,N-diisopropylethylamine (0.12 g, 0.93 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.04 g, 0.06 mmol), tris(dibenzylideneacetone)dipalladium (0.03 g, 0.03 mmol), and dioxane (3 mL) were added to the reaction flask. After nitrogen substitution three times, the temperature was raised to 108°C and stirred for 16 hours. LCMS showed that the reaction was complete. The reaction solution was purified by silica gel column chromatography (dichloromethane / ethyl acetate: 50-90%) to give the off-white product 159b (50 mg, yield: 44.16%). MS m / z [M+H] + :371.2.
[0418] 3. (Compound 159c)
[0419] Compound 159b (50 mg, 0.13 mmol), N-chlorosuccinimide (170 mg, 1.3 mmol), acetic acid (3 mL), and water (1 mL) were added to the reaction flask. The mixture was stirred at room temperature for 3 hours. LCMS showed that the reaction was complete. Water (20 mL) was added to the reaction solution, and the pH was adjusted to 7-8 with saturated sodium carbonate solution. The solution was extracted with dichloromethane (30 mL*2), separated, washed with water, washed with saturated brine, concentrated, and purified on a silica gel column (ethyl acetate / dichloromethane: 30-80%) to obtain the product 159c as a yellow oil (20 mg, yield: 47.75%). MS m / z [M+H] + :311.1.
[0420] 4. (Compound 159d)
[0421] Compound 159c (20 mg, 0.064 mmol), hydrazine hydrate (0.1 mL), and ethanol (2 mL) were added to the reaction flask. The mixture was heated to 80°C and stirred for 2 hours. LCMS indicated that the reaction was complete. The reaction solution was concentrated to afford crude product 159d (19 mg, 100% yield), which was used directly in the next reaction. MS m / z [M+H] + :297.1.
[0422] 5. (Compound 159e)
[0423] Compound 159d (10 mg, 0.034 mmol), triethylamine (10 mg, 0.099 mmol), and dichloromethane (2 mL) were added to the reaction flask. Difluoroacetic anhydride (12 mg, 0.069 mmol) was added dropwise at 0°C and stirred for 2 hours. LCMS indicated the reaction was complete. The reaction solution was concentrated to afford the pale yellow product 159e (10 mg, yield: 79.3%). MS m / z [M+H]+ :375.1.
[0424] 6. (Compound 159)
[0425] To a reaction flask at 0°C, compound 159e (10 mg, 0.027 mmol), p-toluenesulfonyl chloride (3 mg, 0.032 mmol), triethylamine (8 mg, 0.081 mmol), and acetonitrile (2 mL) were added. The mixture was stirred at 25°C for 2 hours. LCMS indicated the reaction was complete. The reaction mixture was filtered and purified by reverse-phase column chromatography to afford product 159 as an off-white solid (2.6 mg, 27.31% yield).
[0426] 1 H NMR (400MHz, DMSO-d6) δ9.54(d,J=2.0Hz,1H),8.91(d,J=2.0Hz,1H),7.29(t,J=51.6Hz,1H),4 .65(s,2H),4.00(q,J=7.6Hz,1H),2.12(s,2H),2.02–1.81(m,4H),1.73(dd,J=7.3,4.4Hz,2H).
[0427] Example 50: (Compound 122)
[0428] Referring to the synthesis method of compound 72 in Example 19, 2-bromo-6-trifluoromethylpyridine was used instead of 4-bromo-1-methyl-1H-pyrazole in the first step to obtain white solid 122.
[0429] 1 H NMR (400MHz, DMSO-d6) δ8.43(d,J=8.4Hz,2H),8.12(t,J=7.8Hz,1H),8.04(d,J=7. 9Hz, 1H), 7.96 (d, J = 8.1Hz, 1H), 7.87–7.81 (m, 3H), 7.75–7.46 (m, 3H), 5.18 (s, 2H).
[0430] Biological tests
[0431] Experimental Example 1.
[0432] The inhibitory activity of the compounds in this application on HDAC6 was evaluated using an enzyme activity assay.
[0433] HDAC6 (Abcam), test compounds, and 20 μM substrate solution (Ac-GAK(Ac)-AMC) were added to a 384-well plate and incubated at 37°C for 30 min. 1 μM Trypsin and 10 μM TSA were added and incubated at room temperature for 15 min. The fluorescence emission intensity was detected at 455 nm with excitation at 360 nm, and the inhibition rate at each concentration, IC 50 The data were fitted using GraphPadPrism 7.0 software.
[0434] The experimental results obtained are shown in Table 1.
[0435] Table 1
[0436] Experimental Example 2.
[0437] The inhibitory activity of the compounds in this application on HDAC1-5 and 7-11 was evaluated using enzyme activity assay.
[0438] Different HDAC isoforms (purchased from BPS), test compounds, and 2.5-40 μM substrate solution (purchased from BPS) were added to a 384-well plate and incubated at 37°C for 30 min. 1 μM Trypsin and 10 μM TSA were added and incubated at room temperature for 15 min. The fluorescence emission intensity was detected at 455 nm with excitation at 360 nm, and the inhibition rate at each concentration, IC 50 The data were fitted using GraphPadPrism 7.0 software.
[0439] The experimental results obtained are shown in Tables 2 and 3.
[0440] Table 2
[0441] Table 3
[0442] Experimental Example 3. Test of α-Tublin Acetylation Level
[0443] Take A375 / HCT116 / HCC827 cells in the logarithmic growth phase, digest them with trypsin cell digestion solution, centrifuge, count, and plate them into 96-well plates (30,000 cells / well) at an appropriate cell density, 100 μL per well, and seal them with an appropriate amount of PBS. The next day, treat the cells with different concentrations of compounds (starting concentration is 100 μM, 5-fold dilution, and 9 concentration gradients are set). After 6 hours, aspirate the culture medium and wash them twice with 100 μL of PBST. The cells are then fixed with 4% paraformaldehyde and incubated at room temperature for 20 minutes. Discard the fixative and wash the cells with PBST. Add 150 μL of special blocking solution (containing 1% Triton-100) to each well, block for 2 hours at room temperature, and wash away the excess blocking solution with PBS. α-tubulin (DM1A) mouse mAb and acetyl-α-tubulin (Lys40) (D20G3) XP rabbit mAb were diluted at a ratio of 1:2000 with 0.033% Triton-100 blocking solution, added to 96-well plates, and incubated overnight at 4°C. A blank control group was also set up. The next day, the plates were washed twice with PBST and the secondary antibody anti-mouse IgG (H+L) (DyLight TM 680 conjugate) and anti-rabbit IgG (H+L) (DyLight TM 800 conjugate) and added to a 96-well plate, incubated at room temperature for 2 h, washed twice with PBST and once with PBS, and the fluorescence signals at 700 nm and 800 nm were detected using a Li-COR Odyssey dual-color near-infrared laser imager.
[0444] The experimental results obtained are shown in Table 4.
[0445] Table 4
[0446] Experimental Example 4. Stability Test
[0447] Test compounds were assessed for their one-phase metabolic stability in liver microsomes of CD-1 mice (MLM), Sprague-Dawley rats (RLM), beagle dogs (DLM), cynomolgus monkeys (CLM), and humans (HLM).
[0448] Experimental system:
[0449] The animal and human liver microsomes used in this test system were purchased from Xenotech, Corning or other qualified suppliers and stored in a freezer below -60°C before use.
[0450] Experiment Introduction:
[0451] Test and control compounds were incubated with animal and human liver microsomes at 37 ± 1°C for a specified period of time, with a maximum incubation time of 60 minutes. Samples were removed at designated time points and the reaction was terminated with acetonitrile or other organic solvent containing an internal standard. After centrifugation, the resulting supernatant was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS / MS).
[0452] Experimental methods:
[0453] 1. Preparation of Buffer
[0454] Dissolve 73.21 g of potassium phosphate dibasic trihydrate and 10.78 g of potassium dihydrogen phosphate in 4000 mL of ultrapure water. Adjust the pH of the solution to 7.40 ± 0.10 using 10% phosphoric acid or 1 M potassium hydroxide, for a final concentration of 100 mM.
[0455] 2. Preparation of working solution
[0456] The test sample powder is prepared into a stock solution of a certain concentration using DMSO or other organic solvents, and then further diluted with a suitable organic solvent.
[0457] The control compounds testosterone, diclofenac, and propafenone were prepared as 10 mM stock solutions in DMSO and then further diluted in appropriate organic solvents.
[0458] 3. Preparation of Liver Microsome Solution
[0459] Dilute each microsome to a 2x working solution using 100 mM potassium phosphate buffer. The final concentration of microsomes in the reaction system is 0.5 mg / mL.
[0460] 4. Preparation of reduced nicotinamide adenine dinucleotide phosphate (NADPH) regeneration system
[0461] Weigh an appropriate amount of nicotinamide adenine dinucleotide phosphate (NADP) and isocitrate (ISO) powder, dissolve in magnesium chloride solution, and vortex to mix thoroughly. Add an appropriate amount of isocitrate dehydrogenase (IDH) and gently invert to mix thoroughly. The final concentrations in the reaction system are: 1 mM NADP, 1 mM magnesium chloride, 6 mM ISO, and 1 unit / mL IDH.
[0462] 5. Preparation of Stop Solution
[0463] The stop solution is prepared with acetonitrile or other organic solvent containing an internal standard (tolbutamide or other suitable compound). The prepared stop solution is stored in a refrigerator at 2-8°C.
[0464] 6. Incubation Process
[0465] Incubations will be performed in 96-well plates. Prepare eight incubation plates, designated T0, T5, T15, T30, T45, T60, Blank60, and NCF60. The first six plates correspond to reaction time points of 0, 5, 15, 30, 45, and 60 minutes, respectively. In the Blank60 plate, no test or control compound is added, and a sample is taken after 60 minutes of incubation. In the NCF60 plate, potassium phosphate buffer is used instead of the NADPH regeneration system solution and incubated for 60 minutes. All conditions are replicated in triplicate.
[0466] Mix the microsomes with the test article or control compound, then preincubate the Blank60, T5, T15, T30, T45, and T60 plates (excluding T0 and NCF60) in a 37°C waterbath for approximately 10 minutes. Add the stop solution to the T0 plate, followed by the NADPH regeneration system working solution. In the NCF60 plate, 98 μL of potassium phosphate buffer was added to each well to initiate the reaction. After the preincubation period, 98 μL of the NADPH regeneration system working solution was added to each well of the Blank60, T5, T15, T30, T45, and T60 plates to initiate the reaction. The reaction temperature was 37 ± 1°C, and the final reaction volume was 200 μL. The reaction system contained 0.5 mg / mL microsomes, 1.0 μM substrate, 1 mM NADP, 6 mM ISO, and 1 unit / mL IDH.
[0467] The reaction was terminated by adding cold stop solution containing internal standard to the reaction plate at 5, 15, 30, 45 and 60 minutes, respectively.
[0468] All reaction plates were shaken and centrifuged at 3220 × g for 20 minutes at 4°C. The supernatant was diluted to a certain ratio and then analyzed by LC-MS / MS.
[0469] Sample analysis
[0470] Sample analysis was performed using liquid chromatography-tandem mass spectrometry (LC-MS / MS) without a standard curve or quality control samples. Semiquantitative determination was performed using the ratio of the analyte peak area to the internal standard peak area. Analyst software (Sciex, Framingham, Massachusetts, USA) was used for analyte and internal standard retention times, chromatogram acquisition, and chromatogram integration.
[0471] The CV of the internal standard peak area in each matrix should be within 20% for each analytical run.
[0472] Data Analysis
[0473] The in vitro elimination rate constant ke of the compound was obtained by converting the ratio of the compound to the internal standard peak area into a residual rate using the following formula:
[0474] CL int(mic) =0.693 / T 1 / 2 / Microsomal protein content (microsomal concentration during incubation mg / mL)
[0475] CL int(liver) =CL int(mic) × amount of microsomal protein in the liver (mg / g) × liver weight to body weight ratio
[0476] According to the well stir model, the hepatic intrinsic clearance and hepatic clearance can be converted using the following formula.
[0477] CL (liver) =(CL int(liver) *Q h ) / (CL int(liver) +Q h )
[0478] The parameters in the formula are shown in the table below.
[0479] [1]Brian Davies and Tim Morris,Physiological Parameters in Laboratory Animals and Human.Pharmaceutical Research,Vol.10No.7,1993
[0480] [2]Journal of Pharmacology and Experimental Therapeutics,1997,283(1):46-58.
[0481] The experimental results obtained are shown in Table 5.
[0482] Table 5
[0483] Experimental Example 5. Pharmacokinetic test in mice
[0484] In this experiment, the pharmacokinetic behavior of the test compound was investigated in BALB / c mice after intravenous (IV) and oral (PO) administration.
[0485] On the day of administration, the actual body weight of the mice was weighed and the administration volume was calculated. There were 3 mice in each group, and two groups of tests were performed for each compound. One group was administered with a single intravenous injection, and the other group of mice was administered with a single oral gavage. Whole blood samples were collected at the specified time (0.25, 0.5, 1, 2, 4, 8, and 24 hours after administration) by orbital bleeding. After blood sample collection, it was immediately transferred to a labeled commercial sample tube containing K2-EDTA (0.85-1.15 mg), followed by centrifugation (3200x g, 4°C, 10 minutes) and plasma was collected. The plasma was transferred to a pre-cooled centrifuge tube, quickly frozen in dry ice, and then stored in an ultra-low temperature freezer at -60°C or lower until LC-MS / MS analysis.
[0486] Plasma concentrations were determined using LC-MS / MS. Plasma concentration data for compounds 1 and 2 were analyzed using a non-compartmental model using WinNonlin Version 6.3 (Pharsight, Mountain View, CA) pharmacokinetic software. Pharmacokinetic parameters were calculated using the linear-log trapezoidal method.
[0487] The experimental results obtained are shown in Table 6.
[0488] Table 6
[0489] Experimental Example 6. Pharmacokinetic test in rats
[0490] In this experiment, the pharmacokinetic behavior of the test compound was investigated in SD rats after intravenous (IV) and oral (PO) administration.
[0491] On the day of administration, the actual body weight of the rats was weighed and the administration volume was calculated. There were 3 rats in each group, and two groups of tests were performed for each compound, one group was administered with a single intravenous injection, and the other group was administered with a single oral gavage. Whole blood samples were collected at the specified time (0.25, 0.5, 1, 2, 4, 8, 24h after administration) by blood sampling from the jugular vein. After blood sample collection, it was immediately transferred to a labeled commercial sample tube containing K2-EDTA (0.85-1.15mg), followed by centrifugation (3200x g, 4°C, 10 minutes) and plasma was collected. The plasma was transferred to a pre-cooled centrifuge tube, quick-frozen in dry ice, and then stored in an ultra-low temperature freezer at -60°C or lower until LC-MS / MS analysis.
[0492] Plasma concentrations were determined using LC-MS / MS. Plasma concentration data were analyzed using WinNonlin Version 6.3 (Pharsight, Mountain View, CA) pharmacokinetic software using a non-compartmental model. Pharmacokinetic parameters were calculated using the linear-log trapezoidal method.
[0493] Experimental Example 7. Ratio of drug concentration in brain and blood of mice
[0494] On the day of administration, the actual body weight of the mice was weighed and the administration volume was calculated. The compound was administered by a single intravenous injection (IV) or oral gavage (PO) to each group of 9 mice. Whole blood samples were collected at the specified time by orbital bleeding. After blood sample collection, it was immediately transferred to a labeled commercial sample tube containing K2-EDTA (0.85-1.15 mg), followed by centrifugation (3200x g, 4°C, 10 minutes) and plasma was collected. The plasma was transferred to a pre-cooled centrifuge tube, quickly frozen in dry ice, and then stored in an ultra-low temperature freezer at -60°C or lower until LC-MS / MS analysis. 20 μL of plasma sample or brain tissue homogenate was added to 80 μL of internal standard solution (50 ng / mL propafenone in acetonitrile). The plate was sealed with a film sealer at 165°C, shaken with a microshaker (maximum speed) for 10 minutes, and centrifuged at 4000 rpm in a low-speed benchtop centrifuge for 20 minutes. 10 μL of the supernatant was removed and added to 90 μL of acetonitrile. The plate was vortexed and sealed with a film sealer at 165°C. After vortexing, 1 μL of the supernatant was collected for LC-MS / MS analysis. Plasma drug concentration data were analyzed using WinNonlin Version 6.3 (Pharsight, Mountain View, CA) pharmacokinetic software using a non-compartmental model. Pharmacokinetic parameters were calculated using the linear-log trapezoidal method.
[0495] Data processing: The ratio of drug concentration in brain and blood of mice at the same time point = drug concentration in brain tissue / drug concentration in plasma
[0496] Experimental Example 8. hERG inhibition test
[0497] HEK293 cells were cultured in DMEM medium containing 10% fetal bovine serum and 0.8 mg / mL G418 at 37°C and 5% CO2. TM After express digestion, centrifugation was performed and the cell density was adjusted to 2 × 10 6cells / mL, then gently mix the cells on a room temperature balanced shaker for 15-20 minutes, and perform patch clamp detection on the machine. The culture medium of the prepared cells was replaced with extracellular fluid. The intracellular and extracellular fluids were aspirated from the liquid pool and added to the intracellular fluid pool, cell and test substance pool of the QPlate chip respectively. The whole-cell patch clamp records the voltage stimulation of the whole-cell hERG potassium current, and the experimental data is collected and stored by Qpatch. The compound started at 30μM, diluted 3 times, and 6 concentration points were set. Each drug concentration was set to be administered twice for at least 5 minutes. The current detected in the external fluid without the compound for each cell was used as its own control group, and at least two cells were used for each concentration to repeat the test twice independently. All electrophysiological experiments were performed at room temperature.
[0498] Data analysis: First, the current after each drug concentration is normalized with the blank control current. Then calculate the inhibition rate corresponding to each drug concentration Calculate the mean and standard error for each concentration and calculate the half-inhibitory concentration for each compound: The above equation was used to perform nonlinear fitting of the dose-dependent effect, where Y represents the inhibition rate, C represents the concentration of the test substance, and IC 50 is the half-inhibitory concentration, and HillSlope represents the Hill coefficient. Curve fitting and IC 50 The calculations were completed using Graphpad software.
[0499] Experimental Example 9. Cytochrome oxidase P450 inhibition test
[0500] 1) Preparation of buffer solution:
[0501] 100mM K-Buffer: Mix 9.5mL of stock solution A with 40.5mL of stock solution B, adjust the total volume to 500mL with ultrapure water, and titrate the buffer to pH 7.4 with KOH or H3PO4.
[0502] Stock solution A (1M potassium dihydrogen phosphate): 136.5g potassium dihydrogen phosphate in 1L water;
[0503] Stock solution B (1M potassium dihydrogen phosphate): 174.2g potassium dihydrogen phosphate in 1L water.
[0504] 2) Preparation of test substance
[0505] The test substance powder is prepared into a stock solution of a certain concentration using DMSO or other organic solvents, and then further diluted with a suitable organic solvent.
[0506] 3) In vitro incubation
[0507] The in vitro incubation system of liver microsomes for CYP450 enzyme metabolic phenotype studies is a biochemical reaction carried out under conditions simulating physiological temperature and physiological environment, with the prepared liver microsomes supplemented with redox coenzymes and enzyme-specific selective inhibitors.
[0508] 4) Detection of parent drug or metabolites
[0509] The concentration of parent drug or its metabolites in the incubation solution was determined by LC-MS / MS.
[0510] Experimental Example 10. Human, rat, and mouse plasma protein binding experiment
[0511] (1) Solution preparation: 0.05 M sodium phosphate and 0.07 M NaCl buffer solutions, control compounds (the final concentration of warfarin and quinidine in the system is 1 μM) and drug solution (final concentration is 1 μM) were prepared respectively.
[0512] (2) Dialysis membrane pretreatment: First, soak in distilled water for 60 minutes; then add a 20% (v / v) ethanol solution (diluted with distilled water) and continue soaking for 20 minutes until the start of the experiment. Rinse twice with distilled water before use to remove excess ethanol.
[0513] (3) Plasma pretreatment: 1) Thaw human, rat, and mouse plasma at room temperature. After thawing, centrifuge at a maximum speed of 2000 × g at room temperature for 5 minutes and retain the supernatant (freeze-thaw of plasma will produce fiber precipitation; plasma samples should be kept at room temperature for the rest of the experiments); 2) Detect the plasma pH value and adjust the pH to 7.4 ± 0.02 by adding a small amount of solid powdered NaH2PO4.
[0514] (4) Control group and test group: 100 μL of plasma solution containing positive control or test compound was added to the donor end of the equilibrium dialysis device, and 100 μL of blank buffer was added to the receiver end.
[0515] (5) Incubate the equilibrium dialysis apparatus at 37°C and 100 rpm for 5 hours.
[0516] (6) Preparation of T0 samples for the control group and the test group: Take 25 μL of plasma solution containing the positive control or the test compound and add 25 μL of blank buffer.
[0517] (7) After the control group and the experimental group were incubated for 5 hours, 25 μL of the sample at the administration end was taken and added with 25 μL of blank buffer; 25 μL of the sample at the receiving end was taken and added with 25 μL of blank plasma.
[0518] (8) All samples were added with 200 μL of acetonitrile containing the internal standard. The samples were vortexed for 10 minutes and then centrifuged at 4000 rpm for 10 minutes. The prepared samples were then submitted for UPLC-MS / MS analysis. Note: The internal standard was 40 ng / mL tolbutamide.
[0519] (9) Data processing
[0520] The plasma protein binding rate of the test compound was calculated by testing the T0 sample, the samples from the donor side and the acceptor side after 5 hours of equilibrium dialysis according to the following formula:
[0521] Binding rate % = 100 × ([dose end] 5h - [receiver end] 5h) / [dose end] 5h
[0522] Experimental Example 11. Mutagenicity Detection of Pollutants
[0523] The test strains used in this mutagenicity assay are auxotrophic Salmonella typhimurium strains TA98 and TA100. The assay is conducted in 6-well culture plates with or without the presence of the S9 metabolic activation system, along with a solvent control (DMSO) and a positive control, with two replicates per treatment group. Five compound concentrations are administered, ranging from 62.5 to 1000.0 μg / well (equivalent to 312.5 to 5000.0 μg / dish in a standard Ames assay). The plates are incubated at 37°C for 48-72 hours, after which bacterial toxicity is assayed in each well and the number of mutant colonies is counted. A test compound is considered positively mutagenic for the test strain when the number of revertant colonies in the test compound group exceeds by more than twice the number of spontaneous revertant colonies in the solvent control group, and this is reproducible and dose-dependent.
[0524] Dimethyl sulfoxide (DMSO) was used to dissolve the test substances and served as a negative (solvent) control. In the S9-free group (-S9), 2-nitrofluorene and sodium azide were used as positive controls for TA98 and TA100, respectively; in the S9-containing group (+S9), 2-aminofluorene was used as a positive control for TA98 and TA100, respectively.
[0525] In addition to those described herein, various modifications of the present invention will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application (including all patents, patent applications, journal articles, books, and any other disclosures) is incorporated herein by reference in its entirety.
Claims
1. A compound or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound, or prodrug thereof, wherein the compound has the structure of formula (I): in L is selected from a direct bond, -C 1-6 Alkylene-, -C 2-6 Alkenylene- and -C 2-6 Alkynylidene-; X is CR 6 or N; Y is CR 4 or N; Z is CR 5 or N; R 1 Selected from H, halogen, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R a 、-OC(=O)R a 、-OC(=O)NR a R b 、-C(=O)OR a 、-OR a 、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR a R b 、-NR a R b 、-C(=O)NR a R b 、-NR a -C(=O)R b 、-NR a -C(=O)OR b 、-NR a -S(=O)2-R b 、-NR a -C(=O)-NR a R b 、-C 1-6 Alkylene-OR a 、-C 1-6 Alkylene-NR a R b and-OC 1-6 Alkylene-NR a R b ; R 2 and R 3 Each independently selected from H, halogen, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R a 、-OC(=O)R a 、-OC(=O)NR a R b 、-C(=O)OR a 、-OR a 、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR a R b 、-NR a R b 、-C(=O)NR a R b 、-NR a -C(=O)R b 、-NR a -C(=O)OR b 、-NR a -S(=O)2-R b 、-NR a -C(=O)-NR a R b 、-C 1-6 Alkylene-OR a 、-C 1-6 Alkylene-NR a R b and-OC 1-6 Alkylene-NR a R b ; or R 2 and R 3 Together they form an oxo group (=O); or R 2 and R 3 Together with the carbon atom to which it is connected, it forms C 3-6 Cycloalkyl or 3-10 membered heterocyclic group; R 4 、R 5 and R 6 Each independently selected from H, halogen, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R a 、-OC(=O)R a 、-OC(=O)NR a R b 、-C(=O)OR a 、-OR a 、-SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR a R b 、-NR a R b 、-C(=O)NR a R b 、-NR a -C(=O)R b 、-NR a -C(=O)OR b 、-NR a -S(=O)2-R b 、-NR a -C(=O)-NR a R b 、-C 1-6 Alkylene-OR a 、-C 1-6 Alkylene-NR a R b and-OC 1-6 Alkylene-NR a R b ; R a and R b Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 Aralkyl; The above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl groups are each optionally substituted at each occurrence with one or more substituents independently selected from the group consisting of halogen, -OH, =O, -NH2, -CN, -NO2, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R c 、-OC(=O)R c 、-OC(=O)NR c R d 、-C(=O)OR c 、-OR c 、-SR c 、-S(=O)R c 、-S(=O)2R c 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)NR c R d 、-NR c -C(=O)R d 、-NR c -C(=O)OR d 、-NR c -S(=O)2-R d 、-NR c -C(=O)-NR c R d 、-C 1-6 Alkylene-OR c 、-C 1-6 Alkylene-NR c R d and-OC 1-6 Alkylene-NR c R d The alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl groups are further optionally substituted by one or more substituents independently selected from the following: halogen, -OH, =O, -C(=O)O-tert-butyl, -NH2, -CN, -NO2, C 1-6 Alkyl, halogenated C 1-6 Alkyl, -OC 1-6 Alkyl, -O-halogenated C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 Aralkyl, preferably, the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl are further optionally substituted by one or more substituents independently selected from the following: halogen, -OH, =O, -C(=O)O-tert-butyl, -NH2, -CN, -NO2, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 aralkyl; and R c and R d Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 Aralkyl, said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl further optionally substituted by one or more substituents independently selected from the following: halogen, -OH, =O, -C(=O)O-tert-butyl, -NH2, -CN, -NO2, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 Aralkyl.
2. The compound of claim 1 or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound or prodrug thereof, wherein L is a direct bond or -C 1-6 Alkylene-, wherein the alkylene is optionally substituted by one or more substituents independently selected from the group consisting of: -OH, -OCH3, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-14 membered heteroaryl, said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl further optionally substituted by one or more halogen or C 1-6 Alkyl substitution; Preferably, L is a direct bond or -C 1-6 Alkylene-, wherein the alkylene is optionally substituted by one or more substituents independently selected from the group consisting of: -OH, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-14 membered heteroaryl, said cycloalkyl, heterocyclyl, aryl and heteroaryl further optionally substituted by one or more halogen or C 1-6 Alkyl substitution; Preferably, L is a direct bond, methylene or ethylene, wherein the methylene and ethylene are optionally substituted by one or more substituents independently selected from the group consisting of -OH, -OCH3, methyl, cyclopropyl, phenyl, pyrazolyl, pyridyl, pyrimidinyl and pyridazinyl, which are optionally further substituted by one or more halogens and / or methyl groups; Preferably, L is a direct bond, methylene or ethylene, wherein the methylene and ethylene are optionally substituted by one or more substituents independently selected from the group consisting of -OH, cyclopropyl, phenyl, pyrazolyl and pyridyl, which are optionally further substituted by one or more halogens and / or methyl groups; Preferably, L is a direct bond, -CH2-, -CH2CH2-、 Preferably, L is a direct bond, -CH2-, -CH2CH2-、 3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound, or prodrug thereof, wherein X, Y, and Z are each independently CH, CF, or N.
4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound, or prodrug thereof, wherein R 1 Selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-14 membered heteroaryl; The alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each optionally substituted by one or more substituents independently selected from the following Substitution: halogen, -OH, -CN, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-14 membered heteroaryl, -C(=O)R c 、-OC(=O)R c 、-C(=O)OR c 、-OR c 、-S(=O)2R c 、-NR c R d 、-C(=O)NR c R d 、-NR c -C(=O)R d 、-NR c -C(=O)OR d 、-NR c -S(=O)2-R d and -NR c -C(=O)-NR c R d The above alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl groups are further optionally substituted by one or more substituents independently selected from the following: halogen (such as fluorine), -OH, =O, C 1-6 Alkyl (such as methyl), halogenated C 1-6 Alkyl (such as trifluoromethyl), -OC 1-6 Alkyl (e.g. methoxy) and -O-halogenated C 1-6 Alkyl (such as trifluoromethoxy), preferably, the above alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl are further optionally substituted by one or more substituents independently selected from the following: halogen (such as fluorine), -OH, =O, C 1-6 Alkyl (eg, methyl).
5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound, or prodrug thereof, wherein R c and R d Each occurrence is independently selected from H, C 1-6 Alkyl (such as methyl, ethyl, tert-butyl), C 3-10 Cycloalkyl (e.g. cyclopropyl), 3-10 membered heterocyclic group (e.g. pyrrolidinyl, morpholinyl or piperidinyl optionally substituted by F, preferably piperidinyl optionally substituted by F), C 6-10 Aryl (phenyl optionally substituted by F) and 5-14 membered heteroaryl (e.g. pyridyl), wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are further optionally substituted by one or more substituents independently selected from the group consisting of halogen (e.g. F), -OH, haloC 1-6 Alkyl (such as trifluoromethyl) and C 3-6 Cycloalkyl (eg, cyclopropyl).
6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound, or prodrug thereof, wherein R 1 is selected from methyl, cyclopropyl, cyclohexyl, tetrahydropyrrolyl, tetrahydropyranyl, piperidinyl, morpholinyl, phenyl, pyrazolyl, pyridinyl, pyrimidinyl, pyridazinyl and imidazopyridinyl; each of which is optionally substituted with one or more substituents independently selected from the following: -F, -Cl, -OH, -CN, -NH2, -CH3, -CF3, -CH2CF2CF3, -NHCH2CF3, Preferably, R 1 is selected from methyl, cyclohexyl, tetrahydropyrrolyl, tetrahydropyranyl, piperidinyl, morpholinyl, phenyl, pyrazolyl, pyridinyl and imidazopyridinyl; each of which is optionally substituted by one or more substituents independently selected from the following: -F, -Cl, -OH, -CN, -CH3, -CF3, -CH2CF2CF3, -NHCH2CF3, 7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound, or prodrug thereof, wherein R 1 Has the following structure: in: U and V are each independently CR 8e R 8f NR 8g or O; R 8a 、R 8b 、R 8c 、R 8d 、R 8e 、R 8f and R 8g are each independently H or halogen (e.g., F); and R 9 is -OR c 、-NR c -C(=O)R d 、-NR c R d 、-NR c -C(=O)OR d 、-NR c -S(=O)2-R d 、-NR c -C(=O)-NR c R d 、-OC(=O)R c 。 8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound, or prodrug thereof, wherein R 1 Selected from methyl, Preferably, R 1 Selected from methyl, 9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound, or prodrug thereof, wherein R 2 and R 3 H or C 1-6 Alkyl, preferably H or methyl; or R 2 and R 3 Together they form an oxo group (=O); or R 2 and R 3 Together with the carbon atom to which it is connected, it forms C 3-6 Cycloalkyl, preferably cyclopropyl.
10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound, or prodrug thereof, wherein R 4 、R 5 and R 6 are each independently H or halogen; preferably, R 4 、R 5 and R 6 are each independently H or F.
11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound, or prodrug thereof, wherein the compound has a structure of Formula (II) or Formula (III): in: L' is -C 1-6 Alkylene-, said alkylene being optionally substituted by one or more substituents independently selected from the group consisting of: -OH, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-14 membered heteroaryl; preferably, the alkylene group is optionally substituted by one or more substituents independently selected from the group consisting of -OH, cyclopropyl, and phenyl optionally substituted by one or more halogens; The remaining groups are as defined in any one of claims 1 to 10.
12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotopically labeled compound, or prodrug thereof, wherein the compound is selected from:
13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound or prodrug thereof and one or more pharmaceutically acceptable carriers, wherein the pharmaceutical composition is preferably a solid preparation, a liquid preparation or a transdermal preparation.
14. Use of the compound of any one of claims 1 to 12 or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, metabolite, isotope-labeled compound or prodrug thereof, or the pharmaceutical composition of claim 13 in the preparation of a medicament for preventing or treating an HDAC6-related disease.
15. The method of claim 14, wherein the HDAC6-related disease is selected from cancer or a proliferative disease (e.g., lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, pancreatic cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphoma, myeloma, multiple myeloma, and solid tumors); Wilson's disease, spinocerebellar ataxia, prion disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, amyloidosis, Alzheimer's disease, Alexander disease, alcoholic liver disease, cystic fibrosis, Pick's disease, spinal muscular atrophy, or dementia with Lewy bodies; rheumatoid arthritis, osteoarthritis; rheumatoid spondylitis; psoriasis; inflammatory bowel disease; chronic inflammatory lung disease, eczema, asthma, ischemia / reperfusion injury, ulcerative colitis, acute respiratory distress syndrome, psoriatic arthritis, infectious arthritis, Chronic arthritis, osteoarthritis, osteoarthritis, traumatic arthritis, gouty arthritis, Reiter's syndrome, polychondritis, acute synovitis and spondylitis, glomerulonephritis, hemolytic anemia, aplastic anemia, idiopathic thrombocytopenic purpura, neutropenia, ulcerative colitis, Crohn's disease, host-versus-graft disease, graft-versus-host disease, allograft rejection, chronic thyroiditis, Graves' disease, scleroderma, diabetes mellitus, active liver disease inflammation, primary biliary cirrhosis, myasthenia gravis, multiple sclerosis (MS), systemic lupus erythematosus, atopic dermatitis, contact dermatitis, sunburn, chronic renal insufficiency, Stevens-Johnson syndrome, idiopathic steatorrhea, sarcoidosis, Guillain-Barré syndrome, uveitis, conjunctivitis, keratoconjunctivitis, otitis media, periodontal disease, pulmonary fibrosis, asthma, bronchitis, rhinitis, sinusitis, pneumoconiosis, pulmonary insufficiency syndrome, emphysema, pulmonary fibrosis, or silicosis.
